Allison Brashear MD, MBA

Allison Brashear

Allison Brashear
MD, MBA

Vice President for Health Sciences and Dean, Jacobs School of Medicine and Biomedical Sciences

Department of Neurology

Jacobs School of Medicine & Biomedical Sciences

Contact Information
955 Main Street, Room 6190
Buffalo, New York 14203-1121
Phone: (716) 829-3955
Fax: (716) 829-2179
brashear@buffalo.edu



Education and Training:

  • George Blumenthal Scholar, Center for Studies in Higher Education, Goldman School of Public Policy, University of California, Berkeley (2020)
  • Fellowship, Council of Deans Fellowship, Association of American Medical Colleges (AAMC) (2015)
  • Certificate, Health Sector Management, Duke University, Fuqua School of Business (2012)
  • MBA, Health Sector Management Certificate, Duke University, Fuqua School of Business (2012)
  • Executive Leadership in Academic Medicine (ELAM), Drexel University (2007)
  • Leadership Development for Physicians in Academic Health Centers, Harvard University, Harvard School of Public Health (2004)
  • Mid-Career Women's Leadership, Association of American Medical Colleges (2003)
  • Residency, Department of Neurology, Indiana University School of Medicine (1991)
  • Internship, Department of Medicine, Indiana University School of Medicine (1988)
  • MD, Indiana University School of Medicine (1987)
  • BA, Chemistry, DePauw University (1983)
  • Diplomate, American Board of Electrodiagnostic Medicine (April 1995; recertified September 2005)
  • Diplomate, American Board of Medical Examiners (1988)
  • Diplomate, American Board of Psychiatry and Neurology (June 1993 lifetime; voluntarily recertified February 2016)
  • Executive Leadership Academy (ELA), Center for Studies in Higher Education, Goldman School of Public Policy, University of California, Berkley

Employment:

  • Dean, Jacobs School of Medicine and Biomedical Sciences, UB (2021-present)
  • Vice President for Health Sciences, University at Buffalo (UB) (2021-present)
  • Dean, School of Medicine, University of California, Davis (2019–2021)
  • Physician, University of California Davis Medical Center, Sacramento, CA (2019–2021)
  • Physician, North Carolina Baptist Hospital, Winston-Salem, NC (2005–2019)
  • Professor (Tenured), Neurology, Wake Forest University School of Medicine (2005–2019)
  • Walter C. Teagle Endowed Chair, Neurology, Wake Forest University School of Medicine (2005–2019)
  • Interim Chair, Psychiatry, Wake Forest University School of Medicine (2014–2015)
  • Physician, Davie County Hospital, Bermuda Run, NC (2009–2010)
  • Professor, Neurology, Indiana University School of Medicine (2005)
  • Consulting Physician, Rehabilitation Hospital of Indiana, Indianapolis, IN (2001–2005)
  • Associate Professor, Neurology, Indiana University School of Medicine (2000–2005)
  • Physician, Richard Roudebush VAH, Indianapolis, IN (1991–2005)
  • Physician, University Hospital, Indianapolis, IN (1991–2005)
  • Physician, Wishard Hospital, Indianapolis, IN (1991–2005)
  • Assistant Professor (tenure track), Neurology, Indiana University School of Medicine (1994–2000)
  • Clinical Assistant Professor, Neurology, Indiana University School of Medicine (1991–1994)
See all (7 more)

Awards and Honors:

  • Power 250 (2022)
  • Sacramento 100 Notable Business Leaders in 2021, Education & Health Care, Sacramento Magazine (2021)
  • Outstanding Women Leaders, City of Winston-Salem (2018)
  • Woman of Vision Award, YWCA of Winston-Salem (2010)
  • Park-Tudor Alumni Award, Indianapolis (2009)
  • Community Leader Award (2009)
  • Selected Best Doctors in America (2009-2018)

Grants and Sponsored Research:

  • April 2008–June 2026
    Administrative Supplements: Clinical, Genetic, and Cellular Consequences of Mutations in Na, K-ATP1A3
    NINDS
    Role: Principal Investigator
    $8,808,829
  • August 2018–August 2023
    NeuroNext: Wake Forest NeuroNext Clinical Site (WAKENN). Grant transferred to Dr. Duncan upon Dr. Brashear’s move to UC Davis.
    National Institute of Neurological Disorders and Stroke (NINDS)
    Role: Principal Investigator
    $1,549,990
  • –July 2019
    Early Supported Discharge for Improving Functional Outcomes After Stroke, Executive Committee
    Patient Centered Outcomes Research Institute (PCORI)
    $14,000,153
  • May 2012–May 2019
    Dystonia Coalition (Subcontract: Emory University)
    National Institute of Neurological Disorders & Stroke (NINDS)
    Role: Principal Investigator
    $42,500
  • October 2018–October 2018
    7th Symposium on ATP1A3 function in health and disease. October 2018 meeting
    National Institute of Neurological Disorders and Stroke (NINDS)
    Role: Principal Investigator
    $15,000
  • April 2016–December 2017
    A Phase II, Open-Label, Dose-Escalating Study to Evaluate the Safety and preliminary Efficacy of RTT150 for Injection in Isolated Cervical Dystonia
    Revance, Inc.
    Role: Principal Investigator
    $81,000
  • July 2013–July 2016
    Cervical Dystonia: A Phase IIIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Dysport® Using 2 ml Dilution in Adults with Cervical Dystonia
    Ipsen, Inc.
    Role: Principal Investigator
    $35,235
  • March 2013–July 2016
    Lower Limb Spasticity: BOTOX® Treatment in Adult Patients with Post-Stroke Lower Limb Spasticity
    Allergan, Inc.
    Role: Principal Investigator
    $24,494
  • September 2011–July 2016
    A Phase III, Multi-Center, Prospective, Open-Label, Extension Study to Assess the Long-term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injections Used for the Treatment of Upper Limb Spasticity in Adult Subjects with Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury
    Ipsen, Inc.
    Role: Principal Investigator
    $148,253
  • September 2011–July 2016
    A Phase III, Multi-Center, Prospective, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Dysport® Intramuscular Injections Used for the Treatment of Upper Limb Spasticity in Adult Subjects with Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury
    Ipsen, Inc.
    Role: Principal Investigator
    $82,877
  • July 2011–July 2016
    A Phase III, Multi-Center, Double-Blind, Prospective, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Dysport Used for the Treatment of Lower Limb Spasticity or Traumatic Brain Injury
    Ipsen, Inc.
    Role: Principal Investigator
    $89,850
  • July 2011–July 2016
    A Phase III, Prospective, Multi-Center, Open-Label, Extension Study to Assess the Long-term Safety and Efficacy of Repeated Treatment Dysport Intramuscular Injection in the Treatment of Lower Limb Spasticity in Adult Subjects with Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury
    Ipsen, Inc.
    Role: Principal Investigator
    $64,817
  • June 2013–June 2014
    Contract with NHLBI and NHGRI: Determine if the Mutation of ATP1A3 Identified in the NIH UDP Patient 4694 is a Likely Cause of Ataxia
    National Institutes of Health
    Role: Principal Investigator
    $10,000
  • June 2012–May 2014
    Prospective, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study with Open-Label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Post-Stroke Spasticity of the Lower Limb
    Merz Pharmaceuticals, GmbH
    Role: Principal Investigator
    $38,310
  • June 2012–May 2014
    CD Flex: An Open-Label, Non-Inferiority Study Evaluating the Efficacy and Safety of Two Injection Schedules of Xeomin® (incobotulinumtoxinA) [Short Flex vs. Long] in Subjects with Cervical Dystonia with <=10 Weeks of Benefit from OnabotulinumtoxinA Treatment
    Merz Pharmaceuticals, LLC
    Role: Principal Investigator
    $20,571
  • April 2008–April 2014
    Supplement for Collaborative Activities to Promote Translational Research (CAPTR)
    National Institute of Neurological Disorders and Stroke (NINDS)
    Role: Principal Investigator
    $95,000
  • April 2008–March 2014
    Clinical, Genetic, and Cellular Consequences of Mutations in Na, K-ATPase ATP1A3
    National Institute of Neurological Disorders and Stroke (NINDS)
    Role: Principal Investigator
    $35,520
  • March 2012–February 2014
    Prospective, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study with an Open-Label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Post-Stroke Spasticity of the Upper Limb
    Merz Pharmaceuticals, GmbH
    Role: Principal Investigator
    $27,171
  • September 2009–September 2011
    Cervical Dystonia – Patient Registry for Observation of BOTOX® Efficacy (CD PROBE)
    Allergan, Inc.
    Role: Principal Investigator
    $9,173
  • December 2007–February 2011
    A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Single Treatment Cycle, Parallel Evaluation of the Safety, Efficacy, and Immunogenicity of Two Formulations of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex (Formulations Nos. 9060X and 9525X), Followed by a Blinded Active Treatment Extension of Up to Two Additional Treatment Cycles in Patients with Cervical Dystonia
    Allergan Sales, LLC
    Role: Principal Investigator
    $26,414
  • December 2007–August 2010
    A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Safety Study of Pulmonary Function in Patients with Reduced Lung Function Treated with BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Focal Upper Limb Spasticity Due to Upper Motor Neuron Syndrome
    Allergan Sales, LLC
    Role: Principal Investigator
    $12,560
  • June 2007–July 2010
    Patient Registry of Spasticity (PROS) Care
    Moss Rehab, Albert Einstein Healthcare Network
    Role: Principal Investigator
    $72,748
  • June 2009–May 2010
    Open-Label, Parallel Study to Determine the Efficacy and Safety of Botulinum Neurotoxin A Paired with Rehabilitation Therapy vs. Botulinum Neurotoxin A Alone for the Treatment of Post-Stroke Upper Limb Spasticity
    Biomedical Research Institute of New Mexico
    Role: Principal Investigator
    $75,402
  • May 2006–May 2010
    A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respiratory Impairment
    Allergan, Inc.
    Role: Principal Investigator
    $30,607
  • April 2006–April 2008
    Prospective, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Trial with an Open-Label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Blepharospasm
    Merz Pharmaceuticals, GmbH
    Role: Principal Investigator
    $92,900
  • December 2006–December 2007
    Prospective, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Trial with a Double-Blind, Parallel-Group Extension Period to Investigate the Efficacy and Safety of Different Doses of NT 201 in the Treatment of Cervical Dystonia
    Merz Pharmaceuticals, GmbH
    Role: Principal Investigator
    $84,531
  • March 2006–December 2007
    A Phase III, Prospective, Multi-Center, Open-Label, Extension Study to Assess the Longer-Term Safety and Efficacy of Repeated Treatment of Dysport Intramuscular Injection in the Treatment of Cervical Dystonia
    Ipsen Biomeasure
    Role: Principal Investigator
    $61,692
  • August 2005–October 2005
    Evaluation on Clinically Meaningful Changes after Botulinum Toxin Treatment in Patients with Post-Stoke Spasticity of the Upper and/or Lower Limb
    Merz Pharmaceuticals, GmbH
    Role: Principal Investigator
    $16,891
  • September 2004–August 2005
    Longitudinal Studies of the Identification: The Prevalence and the Natural History of Rapid Onset Dystonia Parkinsonism
    Independent Study, Non-funded
    Role: Principal Investigator
  • May 2003–August 2005
    A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Safety Study of Pulmonary Function in Patients with Reduced Lung Function Treated with BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Focal Upper Limb Post-Stroke Spasticity
    Allergan, Inc.
    Role: Principal Investigator
    $30,905
  • April 2003–August 2005
    Placebo-Controlled Trial of BOTOX® versus Zanaflex® for the Treatment of Subjects with Post-Stroke Upper Limb Spasticity
    Mt. Sinai School of Medicine
    Role: Co-Principal Investigator
    $17,764
  • June 2002–August 2005
    Clinical and Epidemiological Studies of Dystonia
    Investigator Initiated, Non-funded
    Role: Principal Investigator
  • March 2001–August 2005
    An Open-Label Safety and Immunogenicity Study of Myobloc™ (Neurobloc®; Botulinum Toxin Type B) Injectable Solution in Patients with Cervical Dystonia
    Elan Pharmaceuticals
    Role: Principal Investigator
    $168,425
  • July 1991–August 2005
    Indiana Alzheimer’s Disease Core Center
    Indiana Alzheimer’s Disease Core Center
    Role: Co-Investigator
  • March 2004–April 2005
    A Multi-Center Study to Evaluate the Responsiveness of Seven Functional Tasks in Patients with Post-Stroke, Upper Limb Spasticity Receiving a Double-Blind, Placebo-Controlled BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex Treatment Followed by an Open-Label Botox Treatment
    Allergan, Inc.
    Role: Principal Investigator
    $127,166
  • July 2001–April 2005
    Medical Index for Neuromuscular Data (MIND) Registry
    Elan Pharmaceuticals
    Role: Principal Investigator
    $2,225
  • April 2003–January 2005
    A Multi-Center, Open-Label Study of the Safety of Repeated Doses of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Focal Upper Limb Post-Stroke Spasticity
    Allergan, Inc.
    Role: Principal Investigator
    $137,324
  • April 2001–January 2005
    Observational Study of BOTOX® use in Cervical Dystonia
    Allergan, Inc.
    Role: Principal Investigator
    $227,545
  • January 2004–October 2004
    An Observational Study of the Prevalence of Migraine and Other Primary Headache Disorders and Headaches Attributed to Craniocervical Dystonia in a Population of Subjects with Cervical Dystonia
    Allergan, Inc.
    Role: Principal Investigator
    $15,499
  • June 2001–October 2004
    Botulinum Toxin Type B Observational Study (BOS)
    Baylor College of Medicine
    Role: Principal Investigator
    $33,206
  • March 2004–June 2004
    A Multi-Center Study to Evaluate the Reliability and Clinical Meaningfulness of Seven Functional Tasks in Post-Stroke Subjects with and Without Wrist and Finger Flexor Spasticity
    Allergan, Inc.
    Role: Principal Investigator
    $61,693
  • June 1998–August 2003
    A 15-Week, Preliminary, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Aricept in Patients with Dementia Parkinson’s Disease Followed by an Open-Label Extended Evaluation (single site investigator)
    EISAI, Inc.
    Role: Principal Investigator
    $125,000
  • September 2001–July 2003
    Botulinum Toxin Type A Compared to Botulinum Toxin Type B in Cervical Dystonia (Dystonia Study Group)
    University of Rochester
    Role: Co-Principal Investigator
    $21,186
  • December 2001–June 2003
    Electrodiagnostic Blinded Independent Assessment in Carpal Tunnel Syndrome: Pilot Study
    Non-funded
    Role: Co-Principal Investigator
  • January 2002–August 2002
    A Multi-Center Records Review to Evaluate the Dose Stability of New BOTOX® Over Time
    Health Economics Research
    Role: Principal Investigator
    $10,231
  • September 2001–August 2002
    An Open-Label Study of Botulinum Toxin Type B in Upper Limb Spasticity
    Elan Pharmaceuticals
    Role: Principal Investigator
    $54,763
  • July 2001–July 2002
    A Multi-Center Study Evaluating the Utility of Clinical Scales for the Treatment of Focal Upper Limb Spasticity Post-Stroke
    Allergan, Inc.
    Role: Principal Investigator
    $16,000
  • May 2001–June 2002
    A Double-Blind, Single-Site Study of Botulinum Toxin Type B in Upper Limb Spasticity
    Elan Pharmaceuticals
    Role: Principal Investigator
    $73,053
  • May 1999–December 2001
    A Multi-Center, Open-Label Study of the Safety of Repeated Doses of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in the Treatment of Focal Upper Limb Spasticity Post-Stroke
    Allergan, Inc.
    Role: Principal Investigator
    $56,815
  • April 2000–March 2001
    Title: A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Study of Pulmonary Function Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin for the Treatment of Focal Spasticity Post-Stroke
    Allergan, Inc.
    Role: Principal Investigator
    $58,005
  • July 1999–March 2001
    An Open-Label, Dose-Ranging Study of NeuroBloc™ in Upper Limb Spasticity Protocol #AB002, Investigator Initiated
    Elan Pharmaceuticals
    Role: Principal Investigator
    $95,745
  • September 1997–February 2001
    AN 072-351. An Open-Label Safety Study of NeuroBloc™ (Botulinum Toxin Type B) in Patients with Cervical Dystonia
    Athene Neurosciences
    Role: Principal Investigator
    $231,741
  • March 1996–February 2001
    Studies of Cerebral Dopamine Innervation Using [11C]ß-CFT Positron Emission Tomography
    Indiana University Biomedical Research Grant
    Role: Co-Principal Investigator
  • February 1999–December 1999
    A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Study of the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in the Treatment of Upper Limb Spasticity Post-Stroke, Protocol #191622-008-00
    Allergan, Inc.
    Role: Principal Investigator
    $74,770
  • January 1999–December 1999
    A Multi-Center Chart Review to Determine Duration of Clinical Effect of BOTOX® for Patients with Cervical Dystonia
    Health Economics Research
    Role: Principal Investigator
    $4,960
  • October 1999–October 1999
    Inter-rater and Intra-rater Reliability Study of Ashworth Scale and Functional Disability Scale in Upper Limb Post-Stroke Spasticity
    Allergan, Inc.
    Role: Principal Investigator
    $25,000
  • October 1998–February 1999
    A Multi-Center, Retrospective Study of the Clinical Experience of Patients who had Received New Bulk Toxin BOTOX® and 79-11 BOTOX® Serially for the Treatment of Cervical Dystonia Based on a Review of Randomly Selected Clinical Charts
    Allergan, Inc.
    Role: Principal Investigator
    $12,000
  • June 1996–October 1998
    Predicting Impaired Drivers in Alzheimer’s Disease
    Association for the Advancement of Mental Health Research and Education, Inc.
    Role: Principal Investigator
  • June 1997–March 1998
    Protocol AN072-301: A Double-Blind, Placebo-Controlled, Single Dose, Safety and Efficacy Study of BotB (Botulinum Toxin B) in Patients with Cervical Dystonia
    Athena Neurosciences
    Role: Principal Investigator
    $85,616
  • March 1996–March 1998
    Survey of Idiopathic Torticollis Patients Treated with BOTOX® to Determine Discontinuation Reasons
    Investigator Initiated
    Role: Principal Investigator
  • October 1997–February 1998
    An Open-Label, Multi-Center, Clinical Evaluation of the Safety of Intramuscular BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex Manufactured from Neurotoxin Complex Batch BCB2024 in the Management of Cervical Dystonia
    Allergan, Inc.
    Role: Principal Investigator
    $38,565
  • March 1997–February 1998
    Determination of the Reliability and Validity of the Unified Dystonia Rating Scale
    Dystonia Medical Research Foundation
    Role: Contributor
  • November 1996–November 1997
    A Multi-Center, Double-Blind, Placebo-Controlled, Parallel, Dose-Response Clinical Trial of Intramuscular BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Spasticity in Post-Stroke Patients (BTOX 134-8051)
    Allergan, Inc.
    Role: Principal Investigator
    $125,000
  • January 1996–July 1997
    A Multi-Center, Open-Label Clinical Trial of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Pediatric Ambulatory Cerebral Palsy Patients who previously participated in Allergan OCUL-119-8051/OCUL-119R-8051 (An IND Protocol)
    Allergan, Inc.
    Role: Principal Investigator
  • May 1995–June 1997
    A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study of Intramuscular BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Cervical Dystonia
    Allergan, Inc.
    Role: Principal Investigator
    $70,135
  • March 1997–March 1997
    Cervical Dystonia Severity Scale (CDSS) Reliability Study
    Allergan, Inc.
    Role: Principal Investigator
    $28,500
  • July 1992–June 1995
    A Multi-Center, Open-Label Clinical Trial of Oculinum (Botulinum Toxin Type A) Injectable for Pediatric Ambulatory Cerebral Palsy
    Allergan, Inc.
    Role: Principal Investigator
    $138,688
  • July 1992–June 1995
    Gait Analysis in the Form of 3-D Kinematic Analysis Including EMG in Ambulatory Cerebral Palsy Patients in Association with Botulinum Toxin A Treatment
    Allergan, Inc.
    Role: Principal Investigator
    $48,000
  • July 1992–June 1995
    A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Clinical Trial of Oculinum (Botulinum Toxin Type A) Injectable for Pediatric Ambulatory Cerebral Palsy Patients
    Allergan, Inc.
    Role: Principal Investigator
    $78,605
  • July 1991–June 1995
    The Dementias: Indianapolis-Ibadan Comparative Prevalence
    Role: Co-Investigator
See all (60 more)

Journal Articles:

See all (106 more)

Books and Book Chapters:

  • Brashear A, Elovic E, (eds). (2016) Spasticity: Diagnosis and Management (2nd Edition). New York: Demos Medical Publishing.
  • Pathak MS, Brashear A; Truong D, Dressler D, Hallett M, Zachary C (eds). (2014) Spasticity. In: Manual of Botulinum Toxin Therapy (2nd Edition). Cambridge: Cambridge University Press
  • Brashear A; Stacy M, Pathak MS (eds). (2012) Rapid Onset Dystonia-Parkinson Syndrome. In: Handbook of Dystonia (2nd Edition). Informa Healthcare Publishing
  • Brashear A; Reich S (ed). (2005) Rapid-onset dystonia-parkinsonism. In: Movement Disorders: 100 Instructive Cases. Abingdon, UK: Taylor & Francis Group
  • Brashear A; LeDoux MS (ed). (2005) Adult Spasticity. In: Animal Models of Movement Disorders. New York: Elsevier Academic, 679-686.
  • Siemers E, Brashear A. (2002) Other Therapies, Factor SA, Weiner WJ (eds). In: Parkinson’s Disease Diagnosis and Clinical Management. New York: Demos Medical Publishing, 437-443.
  • Brashear A; Biller J (ed). (2002) Approach to the Hyperkinetic Patient. In: Practical Neurology (2nd Edition). Philadelphia: Lippincott-Raven, 333-342.
  • Brashear A; Biller J (ed). (1998) Complications of Botulinum Toxin. In: Iatrogenic Neurology. Boston, MA, Butterworth-Heinemann, 433-437.
  • Farlow MR, Brashear A, Hui S, Schneider L, Unverzagt F, for the Tacrine Study Group; Iqbal K, Mortimer JA, Winblad B, Wisniewski HM (eds.). (1995) The Effects of Tacrine in Patients with Mild Versus Moderate Stage Alzheimer's Disease. In: Research Advances in Alzheimer’s Disease and Related Disorders. Chichester, England: John Wiley & Sons Ltd., 284-292.

Abstracts:

  • Brashear A. (2021) Extension Study to Assess the Safety and Efficacy of Repeated AbobotulinumtoxinA injections in Adults with Upper Limb Spasticity. American Academy of Neurology Annual Meeting. Vancouver, (Nov), (P3-307)
  • Esquenazi A, Brashear A, Suarez G, Vilain C, Picaut P, Gracies JM. (2021) Importance of Walking Speed Assessment as an Indicator of Functional Improvement in Adults with Spastic Hemiparesis after Repeat Administrations of AbobotulinumtoxinA (Dysport®). American Journal of Physical Medicine & Rehabilitation, AAP February 2018. Atlanta, Georgia (Mar) a1-a131 Poster
  • M. Finger, L. Madden, K. Ruckart, K. Downes, J. Cook, B. Snively, A. Brashear, Haq I. (2019) Auditory-Perceptual Voice and Speech Evaluation in ATP1A3-positive Patients. Mov Disord, (Nov) suppl 2
  • Haq I, Snively B, Sweadner K, Suerken C, Cook J, Ozelius L, Miller C, Whitlow C, Brashear A. (2019) RDP is associated with bulbar and limb weakness: broadening the phenotype of ATP1A3 + Rapid-Onset Dystonia-Parkinsonism (RDP). American Academy of Neurology Annual Meeting. Philadelphia, Pennsylvania (May), (S53.002)
  • Brashear A, Truong D, Comella C, Jankovic J, Patel A, Prawdzik G, Rubio R, Chehrenama M. (2019) Immunogenicity of DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia from a Phase 2 Dose-Escalation Multicenter Study. American Academy of Neurology Annual Meeting. Philadelphia, Pennsylvania (May), (P4.8-012)
  • Wilson C, Cook J, Snively B, Jung Y, Kim J, Sweadner K, Haq I, Ozelius L, Brashear A, Whitlow C. (2019) Neural Correlates Associated with Executive Function in Patients with ATP1A3 Mutation. American Academy of Neurology Annual Meeting. Philadelphia, Pennsylvania (May), (S41.008)
  • Whitlow C, Kim D, Kim J, Jung Y, Cook J, Snively B, Haq I, Sweadner K, Ozelius L, Brashear A. (2019) Effects of ATP1A3 Mutations on Default Mode Network Connectivity. American Academy of Neurology Annual Meeting. Philadelphia, Pennsylvania (May), (N1.002)
  • Turner-Stokes, Ashford, Fheodoroff, Jacinto, Brashear, Maisonobe, Lysandropoulos. (2019) Botulinum Toxin A in Upper Limb Spasticity Management: Changing Clinical Practice. Data from the Upper Limb International Spasticity Programme. IBIA. Toronto, (Mar)
  • Patel, Turner-Stoke, Ashford, Jacinto, Fheodoroff, Brashear, Maisonobe, Balcaitiene. (2018) Botulinum Toxin A in Upper Limb Spasticity Management: Baseline Data from the Upper Limb International Spasticity-III Study. AAPM&R Annual Assembly; Physical Medicine and Rehabilitation. (Oct), (10(9S1), S25-S26)
  • Dressler D, Truong D, Comella C, Jankovic J, Brashear A, Patel A, Prawdik G, Babbar S. (2018) Immunogenicity of DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia from a Phase 2 Dose-escalation Multicenter Study. (Poster). XXIII World Congress on Parkinson’s Disease and Related Disorders. Lyon, (Aug), (A-1003-0007-00146) Poster
  • Esquenazi A, Brashear A, Deltombe T, Volteau M, Vilain C, Picaut P, Gracies JM. (2018) Repeated abobotulinumtoxinA injections benefit walking speed, step length and cadence in adults with spastic hemiparesis due to stroke or traumatic brain injury. ePoster. Annals of Physical and Rehabilitation Medicine, ISPRM. Paris, (Jul) Supplement e364 Poster
  • Gracies, Esquenazi, Brashear, Magali, Philippe, Oyku. (2018) Treatment frequency for long-term efficacy of abobotulinumtoxinA injections: a phase 3 study in patients with lower limb spasticity following stroke or traumatic brain injury. ePoster. Annals of Physical and Rehabilitation Medicine, ISPRM. Paris, (Jul) Supplement TBC Poster
  • Snyder D, Patel A, Comella CL, Jankovic J, Truong D, Brashear A, Evatt ML, Oh C, Roman R. (2018) Outcomes of Week-24 Completers and Subjects who had Follow-Up beyond Week 24 after a Single Treatment of DaxibotulinumtoxinA for Injection (RT002): Results of a Phase 2, Open-Label, Does Escalating Study in Isolated Cervical Dystonia. Neurology Journal, Physiatry ’18, the Association of Academic Physiatrists Annual Meeting (February 2018). Atlanta, Georgia (Apr) Supplement, (P5.037)
  • Turner-Stokes L, Ashford S, Jacinto J, Fheodoroff K, Brashear A, Maisonobe P, Balcaitiene J. (2018) Botulinum Toxin A in Upper Limb Spasticity Management: Baseline Data from the Upper Limb International Spasticity (ULIS)-III Study. WCNR 2018. Mumbai, (Feb)
  • 11. JM Gracies, A Esquenazi, A Brashear, SR Edgley, M O'Dell, P Hedera, B Rubin, P Picaut. (2018) Efficacy and Safety of Repeated AbobotulinumtoxinA Injections in Adults with Lower Limb Spasticity. AAP 2018. Atlanta, Georgia (Feb)
  • Turner-Stokes, Ashford, Fheodoroff, Brashear, Maisonobe, Lysandropoulos, Jacinto. (2018) Time to Retreatment with Botulinum Toxin A in Upper Limb Spasticity Management: Upper Limb International Spasticity (ULIS)-III Study Interim Analysis. Toxins Conference. Copenhagen, (Jan), (Toxicon 2018;156:S110-S11)
  • Isner M, Brashear A, Esquenazi A, Dell MO, Deltombe T, Gonzalez S, Boyer F, Grandoulier AS, Vilain C, Picaut P, Gracies JM. (2017) Duration of Effect of AbobotulinumtoxinA (Dysport) in Adult Patients with Lower Limb Spasticity Post-Stroke or Traumatic Brain Injury. Poster. Annals of Physical and Rehabilitation Medicine 2017, SOFMER 2017. Nancy, (Oct) (S):e26-27 Poster
  • Vilain C, Brashear A, Marciniak C, Jech R, Banach M, Marque P, Grandoulier AS, Picaut P, Gracies JM. (2017) Duration of Effect of AbobotulinumtoxinA (Dysport) in Adult Patients with Upper Limb Spasticity (ULS) Post-Stroke or Traumatic Brain Injury. Poster. Annals of Physical and Rehabilitation Medicine 2017, SOFMER 2017. Nancy, (Oct) (S):e24-25
  • Kocer S, Gracies JM, Brashear A, Esquenazi A, Jech R, Banach M, McAllister P, Kocer S, Grandoulier AS, Vilain C, Picaut P. (2017) Improvement of active movement and function in adults with chronic spastic paresis following repeated treatment with abobotulinumtoxinA (Dysport). Poster. Annals of Physical and Rehabilitation Medicine 2017, SOFMER 2017. Nancy, (Oct) (S):e26 Poster
  • Esquenazi A, Brashear A, Gustavo S, Vilian C, Picaut P, Gracies JM. (2017) Importance of Walking-Speed Assessment as an Indicator of Functional Improvement in Adults with Spastic Hemiparesis after Repeated Administrations of Abobotulinumtoxina. AANEM 2017. (Sep), (P91)
  • Gracies JM, Esquenazi A, Brashear A, O’Dell M, Deltombe T, Gonzalez S, Boyer FC, Grandoulier AS, Vilian C, Picaut P. (2017) Duration of Effect of Abobotulinumtoxia in Adult Patients with Lower Limb Spasticity Post-Stroke or Traumatic Brain Injury. AANEM 2017. (Sep), (P97)
  • Gracies JM, Brashear A, Esquenazi A, Jech R, Dell MO, Deltombe T, Gonzalez S, Boyer F, Grandoulier AS, Vilain C, Picaut P. (2017) Duration of Effect of AbobotulinumtoxinA (Dysport®) in Adult Patients with Lower Limb Spasticity Post-Stroke or Traumatic Brain Injury. Poster. Abstract Book - 90th Congress of the German Society of Neurology, DGN 2017. Leipzig, (Sep) 540, IP 100 Poster
  • Gracies JM, Brashear A, Esquenazi A, Jech R, Banach M, McAllister P, Kocer S, Grandoulier AS, Vilain C, Picaut P. (2017) Improvement of active movement and function in adults with chronic spastic paresis following repeated treatment with abobotulinumtoxinA (Dysport®). Poster. Clinical Rehabilitation 2017, BSRM 2017. Cambridge, (Sep) 842-851 Poster
  • Brashear A, Gracies J, Esquenazi A, Jech R, Banach M, McAllister P, Kocer S, Grandoulier A, Vilain C, Picaut P. (2017) Improvement of active movement and function in adults with chronic spastic paresis following repeated treatment with abobotulinumtoxinA (Dysport®). Poster. Abstract Book - 90th Congress of the German Society of Neurology, DGN 2017. Leipzig, (Sep) 543, IP 103 Poster
  • Jech R, Gracies JM, Brashear A, Marciniak C, Banach M, Marque P, Grandoulier AS, Vilain C, Picaut P. (2017) Duration of Effect of AbobotulinumtoxinA (Dysport®) in Adult Patients with Upper Limb Spasticity (ULS) Post-Stroke or Traumatic Brain Injury. Poster. Abstract Book - 90th Congress of the German Society of Neurology, DGN 2017. Leipzig, (Sep) 543, IP 102 Poster
  • Chung C, Oh C, Rubio R, Comella C, Jankovic J, Brashear A, Patel A. (2017) Safety and Efficacy of DaxibotulinumtoxinA for Injection (RT001) in isolated Cervical Dystonia: Results of a Phase 2, Dose Escalating Study. Parkinson’s Diseases and Movement Disorders. Vancouver, (Jun), (LBA23)
  • Vilain C, Brashear A, Marciniak C, Jech R, Banach M, Marque P, Grandoulier AS, Picaut P, Gracies JM. (2017) Duration of Effect of AbobitulinumtoxinA (Dysport®) in Adult Patients with Upper Limb Spasticity (ULS) Post-Stroke or Traumatic Brain Injury. Poster. Basal Ganglia 2017, German Toxins Congress 2017. Baden-Baden, (May) 1-22:15 Poster
  • Vilain C, Brashear A, Marciniak C, Jech R, Banach M, Marque P, Grandoulier AS, Picaut P, Gracies JM. (2017) Duration of Effect of AbobitulinumtoxinA (Dysport®) in Adult Patients with Upper Limb Spasticity (ULS) Post-Stroke or Traumatic Brain Injury. Poster. SERMEF 2017. Pamplona, (May) Poster
  • Vilain C, Brashear A, Esquenazi A, Jech R, Banach M, McAllister P, Kocer S, Grandoulier AS, Picaut P, Gracies J. (2017) Improvement of active movement and functioning adults with chronic spastic paresis following repeated treatment with abobotulinumtoxinA(Dysport®). Poster. Basal Ganglia 2017, German Toxins Congress 2017. Baden-Baden, (May) 1-22:16 Poster
  • Vilain C, Brashear A, Esquenazi A, Dell MO, Deltombe T, Gonzalez S, Boyer F, Grandoulier AS, Picaut P, Gracies JM. (2017) Duration of Effect of AbobotulinumtoxinA (Dysport®) in Adult Patients with Lower Limb Spasticity Post-Stroke or Traumatic Brain Injury. Poster. Basal Ganglia 2017, German Toxins Congress 2017. Baden-Baden, (May) 1-22:16 Poster
  • Gracies JM, Brashear A, Marciniak C, Jech R, Banach M. Marque P, Grandoulier AS, Vilian C, Pacaut P. (2017) Duration of Effect of Abobotulintoxina (Dysport) in Adult Patients with Upper Limb Spasticity (ULS) Post-Stroke or Traumatic Bain injury. American Academy of Neurology Annual Meeting. Boston, Massachusetts (Apr), (038)
  • Comella C, Brashear A, Jankovic J, Patel A, Truong D, Evatt M, Chung C, Rubio R. (2017) A Phase 2, Open-Label, Dose-Escalating Study to evaluate the safety and preliminary efficacy of Daxibotulinumtoxina for injection in isolated cervical dystonia. American Academy of Neurology Annual Meeting. Boston, Massachusetts (Apr), (021)
  • Whitlow C, Cook J, Snively B, Sweadner K, Haq I, Stacy M, Ozelius L. Brashear A. (2017) Associations between brain structure and motor-related manifestations of rapid-onset dystonia-parkinsonism. American Academy of Neurology Annual Meeting. Boston, Massachusetts (Apr), (015)
  • Sweadner K, Arystarkhove E, Penniston J, Cook J, Swoboda K, Brashear A, Ozelius L. (2017) Structure-Phenotype relationships in ATP1A3 (Na, K-ATPase) diseases. American Academy of Neurology Annual Meeting. Boston, Massachusetts (Apr), (P007)
  • Gracies JM, Brashear A, Marciniak C, Jech R, Banach M, Marque P, Grandoulier AS, Vilain C, Picaut P. (2017) Duration of effect of Abobotulinumtoxin (Dysport) in adult patients with upper limb spasticity (ULS) post stroke or traumatic brain injury. Toxins 2017. Madrid, (Jan), (P3-25)
  • Gracies JM, Brashear A, Esquenazi A, O’Dell M, Deltombe T, Gonzalez S, Boyer F, Grandoulier AS, Vilain C, Picaut P. (2017) Duration of effect of Abobotulinumtoxin (Dysport) in adult patients with lower limb spasticity post stroke or traumatic brain injury. Toxins 2017. Madrid, (Jan), (P3-24)
  • Brashear A. (2017) Sustained incobotulinumtoxinA (Xeomin®) efficacy in upper-limb post-stroke spasticity over 48 weeks in Phase 3, placebo-controlled study with an open-label extension. Toxins 2017: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins. Madrid, (Jan)
  • Kanovsky P, Brashear A, Elovic E, Munin M, Hanschmann A, Hiersemenzel R, Marciniak C. (2016) Sustained incobotulinumtoxina (Xeomin) efficacy in upper limb poststroke spasticity over 48 weeks in Phase 3, Placebo-controlled study with an open-label extension. Toxicon 2016. (Nov), (P3.35)
  • Marciniak C, Brashear A, McAllister P, Rubin, Hedera P, Isaacson S, Picaut P, Gracies JM. (2016) Efficacy and safety of abobotulinumtoxinA (Dysport) in adult hemiparetic patients with upper-limb spasticity previously treated with botulinum toxins. Poster 28. (Nov) Poster
  • Whitlow CT, Cook J, Snively BM, Sweadner KJ, Haq IU, Stacy M, Ozelius, Brashear A. (2016) Associations between brain structure and executive function in patients with rapid-onset dystonia-parkinsonism. Annual Meeting of the American Neurological Associations. Baltimore, Maryland (Oct)
  • Gracies JM, Esquenazi A, Brashear A, Edgley SR, O'Dell M, Hedera P, Rubin, BS, Picaut P. (2016) Efficacy and Safety of Repeated AbobotulinumtoxinA Injections in Adults with Lower Limb Spasticity. Poster. PM&R 2016. New Orleans, Louisiana (Oct), (8(S9):S254;2016) Poster
  • Gracies JM, Esquenazi A, Brashear A, Edgley SR, O’Dell M, Hedera P, Rubin BS, Picaut P. (2016) Efficacy and Safety of Repeated AbobotulinumtoxinA Injections in Adults with Lower Limb Spasticity. (Sep)
  • Whitlow CT, Cook J, Snively BM, Sweadner KJ, Haq IU, Stacy M, Ozelius, Brashear A. (2016) Associations between brain structure and executive function in patients with rapid-onset dystonia-parkinsonism. 5th Symposium ATP1A3 in Disease. London, (Aug), (P15)
  • Gracies JM, Brashear A, Jech R, Picaut P. (2016) Efficacy and Safety of AbobotulinumtoxinA (Dysport®) in the Treatment of Adults with Upper Limb Spasticity: Randomized Double-Blind Placebo-Controlled Phase III Study. ISPRM 2014. Cancun, (Jun), (Pm r 2014; 6(S2):S85)
  • Gracies JM, Brashear A, Jech R, McAllister P, Banach M, Valkovic P, Walker H, Catus F, Vilain C, Picaut P. (2016) Effects of Repeated Injections of Abobotulinumtoxina (Dysport) on Active Movements, Active Function and Spasticity, in Adults with Spastic Paresis in the Upper Limb: Phase III Open-label Extension Study. WCNR 2016. Philadelphia, Pennsylvania (May)
  • Dixon K, Canzona M, Hyde M, Martin S, Bowton D, Wilson J, Brashear A, Sarwal A. (2016) Occurrence and Timeliness of Goals of Care Discussions in the Neurocritical Care Unit. American Academy of Neurology Annual Meeting. Vancouver, (Apr), (P3-224)
  • Brashear A. (2016) Sustained Efficacy with IncobotulinumtoxinA in Upper-Limb Post-Stroke Spasticity Over 48 weeks. American Academy of Neurology Annual Meeting. Vancouver, (Apr), (P3-303)
  • Crumpler J, McDonough, Tucker K, Bowton D, Datar S, Brashear A, Sarwal A. (2016) Institutionally Standardized Education Module and EMR Documentation for Death by Neurological Criteria Evaluation Can Improve Provider Compliance with Guidelines in a Tertiary Care Academic Medical Center. American Academy of Neurology Annual Meeting. Vancouver, (Apr), (P3-218)
  • Sweadner KJ, Toro C, Whitlow CT, Snively BM, Cook JF, Ozelius LJ, Markello TC, Brashear A. (2016) ATP1A3 Mutation in Adult Rapid-Onset Ataxia. PMID: 26990090. PLoS One. (Mar), (11(3):e0151429)
  • O’Dell M, Brashear A, Walker H, Gul F, Edgley S, Wimmer M, Vilain C, Gracies JM. (2015) AbobotylinumtoxinA (Dysport) in the treatment of adult patients with upper-limb spasticity due to traumatic brain injury. AAPM&R. Boston, Massachusetts (Oct), (P36)
  • Jech R, Brashear A, Bensmail D, Loche CM, Isner-Horobetti ME, Remy-Neris O, Stoquart G, Denes Z, Csányi A, Rudzinska M, Timerbaeva SL, Vilain C, Picaut P, Gracies JM. (2015) AbobotulinumtoxinA (Dysport®): doses used to treat upper limb muscles of adults with spasticity participating in a Phase III randomized, double-blind placebo-controlled study. DGN 2015. Congress of the German Society of Neurology. Dusseldorf, (Sep), (P36)
  • Lejeune T, Brashear A, Boyer FC, Hedera P, Kaminska A, Kocer S, O'Dell M, Stoquart G, Timerbaeva, Vecchio, Vilain, Catus F, Picaut P, Gracies JM. (2015) Abobotulinumtoxina (Dysport®): Doses Used to Treat Upper Limb Muscles of Adults with Spasticity Participating in a Phase Iii Randomized, Double-blind Placebo-controlled Study. Journal of Rehabilitation Medicine, Supplement, ISPRM 2015. Berlin, (Jun) 60 (TA188)
  • Brashear A, Cook J, Snively B, Sweadner K, Ozelius L. (2015) ATP1A-3-related Disorders: A Broadening of the Phenotypic and Genotypic Presentation. American Academy of Neurology Annual Meeting. Washington, DC, (Apr), (P2-141)
  • Sweadner K, Cook J, Snively, Ozelius L, Toro C, Brashear A. (2015) A Case of Rapid-Onset Dystonia-Parkinsonism (RDP) with Prominent Ataxia. American Academy of Neurology Annual Meeting. Washington, DC, (Apr), (P2-117)
  • Brashear A, Marciniak C, Edgley S, Gul F, Hedera P, McAllister P, O’Dell M, Rubin Br, Walker H, Vilian C. (2015) A Phase III Randomized, Double blinded, Placebo-controlled Study to Access the Efficacy and Safety of AbobotulinumtoxinA (Dysport) in Adults with Upper Limb Spasticity. American Academy of Neurology Annual Meeting. Washington, DC, (Apr), (S28.001)
  • Gracies JM, Brashear A, McAllister P, Walker H, Marciniak C, Gul F, Edgley S, Picaut P. (2014) Randomized, Double-blind Placebo-controlled Phase III Study of Dysport®, AbobotulinumtoxinA, in the Treatment of Adults with Upper Limb Spasticity. Poster. FANEMAAPM&R. San Diego, California (Nov), (PM&R 2014;6(S9):S327) Poster
  • Gracies JM, Brashear A, Jech R, McAllister P, Banach M, Valkovic P, Walker H, Catus F, Vilain C, Picaut P. (2014) First results of ABot Botulinum Toxin a (DYSPORT®) in the treatment of adults with upper limb spasticity: a randomized double-blind placebo-controlled study. (May)
  • Gracies JM, Brashear A, Jech R, McAllister P, Banach M, Valkovic P, Walker H, Catus F, Vilain C, Picaut P. (2014) AbobotulinumtoxinA (Dysport®) in the Treatment of Adults with Upper Limb Spasticity: First Results of a Randomized, Double-blind Placebo-controlled Study. WCN 2014. Istanbul, (Apr)
  • Brashear A, Cook JF, Snively BM, Ozelius LJ, Sweadner KJ, Whitlow CT. (2013) Imaging results in RDP provide potential insights. Second Symposium on ATP1A3 in disease. Rome, (Sep)
  • Tate J, Brashear A, Whitlow C, Snively B, Ozelius B, Sweadner K, Stacy M, Haq I. (2013) Rapid-onset dystonia-parkinsonism presenting as tremor-dominant Parkinson’s disease. American Academy of Neurology Annual Meeting. San Diego, California (Mar), (P04.161)
  • Devier A, Harnar J, Lopez L, Brashear A, Graham G. (2012) Onabotulinumtoxin A plus rehabilitation improves functional outcome in post-stroke upper limb spasticity: a single-blind, randomized tria. American Neurology Academy Annual Meeting. (Oct), (S904)
  • 62. Whitlow C, Brashear A, Ghetti B, Hagen M, Sweadner K, Maldjian J. (2012) Structural abnormalities in the brain associated with rapid onset dystonia-parkinsonism: a preliminary investigation. American Neurology Academy Annual Meeting. (Apr), (T1770)
  • Ghetti B, Hagen M, Maldjian J, Whitlow C, Ozelius L, Sweadner K, Brashear A. (2012) Rapid onset dystonia-parkinsonism associated with the 1758S ATP1A3 mutation: a neuropathology study of three affected siblings. American Neurology Academy Annual Meeting. (Apr), (T1724)
  • Brashear A. (2012) Psychiatric and neurocognitive morbidity in rapid-onset dystonia Parkinsonism. Abstract. 64th American Academy of Neurology. New Orleans, Louisiana (Apr), (1634)
  • Brashear A. (2011) Movement disorders: atypical Parkinsonism. 63rd American Academy of Neurology Annual Meeting. Honolulu, Hawaii (Apr), (Abstract 3149AAN11D1)
  • Brashear A. (2010) New triggers in rapid-onset dystonia-parkinsonism (RDP). Neurology, (Dec) S19.005
  • Brashear A. (2010) De novo and recurrent mutations in ATP1A3 are common in rapid onset dystonia-parkinsonism. Neurology, (Dec) S19.002
  • Hill DF, Cook JF, Snively BM, Light LS, McCall WV, Boggs NL, Ozelius LJ, Sweadner KJ, Brashear A. (2010) Psychiatric morbidity in rapid-onset Dystonia Parkinsonism. Association for Psychological Science. (Jun)
  • Esquenazi A, Mayer N, Kim S, Brashear A, Elovic E, Francisco G, Yablon S. (2010) Clinical experience effect on care based on results from the Patient Registry of Outcomes in Spasticity (PROS) Care. AAPMR. (Mar)
  • Sacino A, Hampton TG, Lingrel JB, Brashear A, Sweadner KJ. (2009) Rapid onset dystonia-parkinsonism: symptoms in a mouse deficient in Na,K-ATPase x3. Mov Disord, (Dec)
  • Clark A, Raymond D, Kosti V, Barbano R, Tijssen MA, Penniston JT, Bressman SB, Brashear A, Sweadner KJ, Ozelius LJ. (2009) New and recurrent mutations in the ATP1A3 gene in patients with Rapid-onset Dystonia Parkinsonism (RDP). Mov Disord, (Dec)
  • Brashear A. (2009) Relationship between active function and tone in a placebo-controlled study of botulinum neurotoxin vs tizanidine in upper limb spasticity. 2009 ACRM-ASNR Joint Educational Conference. Denver, Colorado (Oct)
  • Brashear A. (2009) The use of botulinum toxin in spasticity and dystonia. 60th Annual Meeting of the American Academy of Neurology. Chicago, Illinois (Apr)
  • Barbano R, Ozelius L, Hill D, Brashear A. (2009) Variable phenotypic expressions of rapid onset dystonia Parkinsonism in a newly discovered Italian family with a T613M mutation in the ATP1A3 gene. Annual American Academy of Neurology Meeting. Seattle, Washington (Apr)
  • Elovic E, Brashear A, Kaelin D, McIntosh R, Liu J, Turkel C. (2008) The effect of repeated treatment of botulinum toxin type A on poststroke, spasticity-related pain: a subgroup analysis of patients in a 12-month trial. Arch Phys Med Rehabil, (Dec) 799-806
  • Simpson DM, Gracies JM, Yablon S, Barbano R, Brashear A, BoNT/Tiz Study Team. (2007) Botulinum neurotoxin vs oral tizanidine in the treatment of upper limb spasticity: a double-blind, placebo-controlled study. AAN Annual Meeting: Late Breaking Science Session. Boston, Massachusetts (May)
  • Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ. (2006) Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology, (Dec)
  • Brashear A, Farmer D, Wood F, Bressman SB, Dobyns WB, Ozelius LO. (2006) ATP1A3 mutations in rapid-onset dystonia Parkinsonism: is there more to the story?. Ann Neurol, (Dec) S10-S11
  • Schoene R, Brashear A, Turkel CC, McIntosh R, Liu J, Brin MF. (2006) A randomized, double-blind, placebo-controlled, parallel group multi-center study evaluating the effect of botulinum toxin type A treatment of pulmonary function in patients with post-stroke focal spasticity. AAPM&R Annual Meeting. Honolulu, Hawaii (Nov)
  • Elovic E, Brashear A, Kaelin D, McIntosh R, Liu J, Turkel CC. (2006) Safety and efficacy of repeated botulinum toxin type A (BoNTA) in the treatment of poststroke, upper limb spasticity: a 12-month trial. 10th International Congress of Parkinson’s Disease and Movement Disorders. Kyoto, (Oct)
  • Brashear A, Hogan P, Watts MW. (2006) Consistency of botulinum toxin type A (BoNT/A; Botox) for cervical dystonia. Neurotoxicity Res, (Apr) S27:231
  • Brashear A. (2006) Patient selection and functional measures in post-stroke spasticity. Neurotoxicity Res, (Apr) S17:220-221
  • Elovic E, Brashear A, Kaelin D, McIntosh R, Liu R, Turkel C. (2006) Safety and efficacy of repeated botulinum toxin type A treatments for focal upper limb poststroke spasticity: results of a 12-month multicenter, open-label trial. Neurotoxicity Res, (Apr) P23:230
  • Jankovic J, Hunter C, Atassi MZ, Brashear A. (2005) BOS Research Group. Botulinum toxin type B observational study (BOS). Mov Disord, (Dec) 105
  • Comella CL, Brashear A. (2005) A multicenter, randomized, double-blind, parallel direct comparison of botulinum toxin type A and type B in cervical dystonia. Mov Disord, (Dec) 103
  • Brashear A. (2005) Dose consistency of botulinum toxin Type A (BoNT/A; BOTOX) for cervical dystonia. 5th International Conference on Basic and Therapeutic Aspects of Botulinum Toxin and Tetanus Toxin. Denver, Colorado (Jun)
  • Brashear A. (2005) Safety and efficacy of repeated botulinum toxin type A treatments for Focal upper limb spasticity: results of a 12-month multicenter, open-label Trial. 5th International Conference on Basic and Therapeutic Aspects of Botulinum Toxin and Tetanus Toxin. Denver, Colorado (Jun)
  • Brashear A, Kuhn ER, McAfee A, Fyffe J. (2003) Double-blind, placebo-controlled trial of botulinum toxin type B in upper limb spasticity. Neurology, (Dec) A30
  • Brin M, Brashear A, Mordaunt J. (2003) Effect of botulinum toxin type A (BoNT-A) therapy on pain frequency and intensity in patients with cervical dystonia. Cephalagia, (Sep) 743
  • Gordon MF, Brashear A, Elovic E, Kassicieh D, Marciniak C, Gonzaga- Camfield R, Liu J, Turkel C. (2002) A multicenter, open-label study of the safety and efficacy of repeated botulinum toxin type A doses in poststroke, focal, upper limb spasticity. Neurology, (Dec) A221
  • Brashear A, Unverzagt F, Kuhn ER, Perkins AJ, Farlow MR, Hui SL. (2002) Simple office tools to predict impaired drivers with dementia. Neurology, (Dec) A275
  • Turkel C, Dru R, Liu J, Botox® Spasticity Study Group. (2002) Double-blind, randomized study of Botox® (botulinum toxin type A) purified neurotoxin complex for treating focal spasticity poststroke. Toxins 2002 meeting. (Jun)
  • Brashear A, McAfee A, Kuhn ER, Ambrosius W. (2001) An open-label trial of botulinum toxin type B in upper limb spasticity. Arch Phys Med Rehabil, (Dec)
  • Brashear A, Gordon MF, Elovic E, Kassicieh D, Marciniak C, Turkel C, Jenkins S. (2001) Botox Post-Stroke Study Group. A multicenter, double-blind, randomized, placebo-controlled, parallel study of the safety and efficacy of Botox (botulinum toxin type A) purified neurotoxin in the treatment of focal upper limb spasticity poststroke. Neurology, (Dec) A78
  • Comella CL and the Dystonia Study Group. (2001) Rating scales for dystonia: A multicenter Assessment of three dystonia rating scales: The unified Dystonia Rating Scale (UDRS), the Burke-Fahn Marsden (BFM), and the Global Dystonia Rating Scale (GDS). Neurology, (Dec) A387
  • Brashear A, Zafonte RD, Lee C, Kuhn ER, Turkel C. (2001) The inter- and intrarater reliability of the Ashworth Scale and Disability Assessment Scale in patients with upper-limb post stroke spasticity. Arch Phys Med Rehabil, (Dec) 1292
  • Magar RS, Marchetti AE, Lau H, Brashear A, Watts MW. (2000) Botulinum toxin type A (Botox®) for cervical dystonia: duration of clinical effec. Mov Disord, (Dec) 151
  • Cullis P, Brashear A, Molho E, O’Brien C, Eadie N, Jenkins S, the Botox® Study Group. (2000) Cervical Dystonia Severity Scale reliability study. Mov Disord, (Dec) 30
  • Comella C, Brashear A, Truong D, Charles D, Hauser RA, Tsui J; Botox® 140-8051 Study Group. (2000) A randomized multicenter, double-blind, placebo-controlled study of original Botox® (botulinum toxin type A) purified neurotoxin complex for the treatment of cervical dystonia. Mov Disord, (Dec) 30
  • Magar RS, Marchetti AE, Lau H, Brashear A, Watts MW. (2000) Botulinum toxin type A (Botox®) for cervical dystonia: duration of clinical effect. Mov Disord, (Dec) 151
  • Factor SA, Adler CA, Brashear A, Brin MF, Comella CL, Dykstra DD, Jankovic J, Lew MF, O’Brien C, Rodnitzky RL, Singer C, Trosch R, Murray JJ, Willmer-Hulme A, Wallace JD, Koller M. (2000) Safety and efficacy of NeuroBloc™ (botulinum toxin type B) in type-A responsive and type-A resistant patients with cervical dystonia. Mov Disord, (Dec) 7
  • Magar RS, Marchetti AE, Lau H, Davis TL, Brashear A, Watts MW. (2000) Treatment algorithm for cervical dystonia. Mov Disord, (Dec) 150
  • Kareken DA, Mulholland GK, Farlow MR, Siemers ER, Kuhn ER, Zheng QH, Fain RL, Hutchings GD, Brashear A. (1999) [11C ]ß-CFT PET imaging of presynaptic dopamine uptake sites in progressive supranuclear palsy. Neurology, (Dec) A350
  • Childers MK, Brashear A, Jozefczk PB, Reding MJ, Dru RM, Lee CH, Joshi TG, Turkel CC, Jenkins CC, Jenkins SW. (1999) A multi-center, double-blind, placebo-controlled dose response trial of botulinum toxin type A (Botox®) in upper limb spasticity post-stroke. Neurology, (Dec) A295
  • Comella CL, Leurgans S, Chmura TA; Dystonia Study Group. (1999) The Unified Dystonia Rating Scale: initial concurrent validity testing with other dystonia scales. Neurology, (Dec) A292
  • Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ, Willmer-Hulme A, Wallace JD, Koller M. (1999) Safety and efficacy of Neurobloc™ (botulinum toxin type-B) in type-A responsive cervical dystonia patients. Neurology, (Dec) A292
  • Kramer PL, Klein C, Schilling K, Ozelius LJ, Mineta M, Farlow MR, deLeon D, Breakefield XO, Bressman SB, Dobyns, WB, Brashear A. (1999) Two families with rapid-onset dystonia-parkinsonism: link to chromosome 19. Neurology, (Dec) A13
  • Brashear A, Truong B, Charles D, Comella C, et al. (1998) A randomized, double-blind, placebo-controlled study of intramuscular Botox® for the treatment of cervical dystonia. Mov Disord, (Dec) P4.243
  • Brashear A, Unverzagt FW, Kuhn ER, Farlow MR, Hui S. (1998) Predicting driving safety in patients with dementia. Neurology, (Dec) A92
  • Comella CL, Siemers ER, Goetz CG, Leurgans S, Stebbins GT; Dystonia Study Group. (1998) Development of the Unified Dystonia Rating Scale: assessment of reliability. Neurology, (Dec) A365
  • Breakefield XO, Klein C, Augood S, Hewitt J, Bressman S, Standaert D, Gonzales-Agosti CH, Mineta M, Ramesh V, Kramer P, Brashear A, Dobyns W, Vieregge P, Penney J, Ozelius L. (1998) Torsion dystonia: Genetic insights into neuronal function. Medizinische Genetik, (Dec) 468-469
  • O’Brien O, Hause RA, Sutton JP, Brashear A, et al. (1998) Evaluation of Botox® manufactured from a new bulk toxin in the open label treatment of cervical dystonia. Mov Disord, (Dec) P4.241
  • Brashear A, P. Cullis, Moiho E, O’Brien C, et al. (1998) Cervical Dystonia Severity Scale (CDSS) reliability study. Mov Disord, (Dec) P4.242
  • Kramer PL, Mineta M, Schilling K, Klein C, Yount J, Bressman S, Farlow M, Breakefield XO, Dobyns WB, Ozelius LJ, Brashear A. (1998) A gene for rapid-onset dystonia-parkinsonism is located on chromosome 19. Am J Hum Genet, (Dec) A295
  • Farlow MR, Lahiri DK, Brashear A, Cyrus PA, Gulanski B. (1998) Metrifonate in the symptomatic treatment of Alzheimer's disease: influence of apolipoprotein E genotype. Neurology, (Dec) A365
  • Brashear A, Kuhn ER, Unverzagt FW, Glazier BS, Farlow MR. (1997) Impaired recognition of traffic signs in demented drivers. Ann Neurol, (Dec) 401
  • Brashear A, Butler IJ, Farlow MR, Dobyns WB. (1997) Homovanillic acid levels in CSF provide a biologic marker in rapid-onset dystonia-parkinsonism. Mov Disord, (Dec) 46
  • Brashear A, Mulholland GK, Qi-Huang Z, Farlow MR, Siemers ER, Dobyns WB, Hutchins G. (1997) [C-11]CFT PET in rapid-onset dystonia-parkinsonism. Neurology, (Dec) P01.116
  • Brashear A, DeLeon D, Bressman S, Farlow M, Dobyns WB. (1996) Rapid-onset dystonia-parkinsonism: a report of a second family. Neurology, (Dec) S40.006
  • Brashear A, Unverzagt FW, Farber MO, Bonnin JM, Garcia JGN, Grober E. (1995) Ethylene oxide neurotoxicity: a cluster of 12 nurses with peripheral and central nervous system toxicity. Neurology, (Dec) P752
  • Chutorian A, Root L; BTA Study Group. (1995) A multicenter, randomized, double-blind, placebo-controlled trial of botulinum toxin type A (BTA) in the treatment of lower limb spasticity in pediatric cerebral palsy. Mov Disord, (Dec) M10
  • Farlow MR, Brashear A, Hui S; Tacrine Study Group. (1994) The effects of tacrine in patients with mild versus moderate stage Alzheimer's disease. Neurobiol Aging, (Dec) A331
  • Hendrie H, Osuntokun B, Hall K, Ogunniyi A, Farlow MR, Gurege O, Unverzagt F, Baiyewu O, Hui S, and the Indianapolis/Ibadan Team. (1994) A comparison of the prevalence of dementia and Alzheimer's disease in community dwelling residents of Ibadan, Nigeria and Indianapolis, USA. Neurobiol Aging, (Dec) A172
  • Brashear A, Dobyns WB, Farlow MR, Kasarskis EJ, Butler IJ. (1994) Variable phenotype presentation of rapid-onset dystonia-parkinsonism. Mov Disord, (Dec) P223
  • Unverzagt FW, Class CA, Brashear A, Farlow MR, Burdine V, Mercado N, Hall KS, Hendrie H and the Indianapolis/Ibadan Collaborative Group. (1994) Psychometric discrimination of mild dementia in an African American Sample. Neurobiol Aging, (Dec) A373
  • Hall K, Ogunniyi A, Hendrie H, Osuntokun B, Hui S, Unverzagt F, Baiyewu O and the Indianapolis/Ibadan Team. (1994) Community screening for dementia in Indianapolis and Ibadan, Nigeria. Neurobiol Aging, (Dec) A173
  • Brashear A, Allard MM, Siemers ER. (1994) Latent onset of focal dystonia after chemotherapy. Mov Disord, (Dec) P165
  • Brashear A, Unverzagt FW, Class CA, Hendrie HC, Farlow MR. (1994) Prediction of driving in Alzheimer's patients with neuropsychologic testing. Neurobiol Aging, (Dec) A437
  • Brashear A, Unverzagt FW, Shekhar A, Farber MR, Garcia JG, Hendrie HC. (1994) Neuropsychiatric and brain flow abnormalities after acute exposure to vapors of organic solvents. Neurology, (Dec) A400
  • Brashear A, Kincaid J. (1993) Causes of the difference in peroneal and tibial compound muscle action potential configuration. Muscle Nerve, (Dec) 1113
  • Dobyns WB, Ozelius LJ, Kramer PL, Brashear A, Farlow MR, Perry TR, Walsh LE, Kasarkis EJ, Butler IJ, Breakefield XO. (1993) Rapid-onset dystonia-parkinsonism. Neurology, (Dec) A350
  • Hendrie HC, Osuntokun BO, Hall, KS, Ogunniyi O, Farlow MR, Brashear A, Burdine VE, Unverzagt FW, Hui SL, Class CA, Musick B, Gureje O, Baiyewu O and the Indianapolis-Ibadan Study Team, Baldereschi M, Amaducci L. (1993) WHO Research Project on Age-Associated Dementias. The Indianapolis-Ibadan dementia project. Sixth Congress of the International Psychogeriatric Association. Berlin, (Sep), (83)
  • Brashear A, Kincaid JC. (1992) The influence of the reference electrode on compound muscle action potential morphology. Electroencephalography and Clinical Neurophysiology, (Dec) 8P
See all (123 more)

Professional Memberships:

  • Association of American Medical Colleges (AAMC) Council of Deans Administrative Board (2022–2023)
  • Great Lakes Health System of Western New York; Member, Board of Directors (2021–present)
  • Buffalo Niagara Medical Campus (BNMC) Board of Directors; Member (2021–present)
  • McKnight Brain Research Foundation Trustee (2020–2023)
  • California Institute of Regenerative medicine (CIRM) Oversight Board; Member (2020–2021)
  • Latinx Physicians of California (LPOC), Board of Directors; Member (2020–2021)
  • California Medical Association; Member (2019–2021)
  • Sierra Sacramento Valley Medical Society; Member (2019–2021)
  • American Board of Psychiatry and Neurology (ABPN) Board of Directors (2015–2023)
  • Association for University Professors of Neurology (AUPN) Executive Council (Board of Directors) (2014–2017)
  • American Academy of Neurology (AAN) Board of Directors; Termed with new rule, unable to serve on AAN and ABPN BOD (2013–2015)
  • American Neurological Association (ANA) Executive Council (Board of Directors) (2012–2014)
  • United Council of Neurological Subspecialties (UCNS) Board of Directors; ANA Representative (Vice Chair) (2011–2012)
  • North Carolina Medical Society, Member (2005–2019)
  • North Carolina Neurological Society, Member; Member (2005–2019)
  • Indiana Neurological Society, President, 2004-2005, Vice-President, 2002-2004, Elected Secretary, 2000-2002 (2000–2005)
  • California Institute of Regenerative Medicine Treatments and Cures Accessibility and Affordability Working Group
See all (7 more)

Presentations:

  • "Reflections on Strategies to Support and Promote Women in Academic Neurology and Psychiatry" American Board of Psychiatry and Neurology Forum on Supporting and Promoting Women in Academic Neurology and Psychiatry (2022)
  • "Career Perspectives and Vision for Clinical and Translational Research" UB Clinical and Translational Science Institute (CTSI) Annual Forum (2022)
  • "The Future of Healthcare" Alpha Omega Alpha Honor Medical Society Induction Ceremony (2022)
  • "Equity, Diversity, and Inclusion (Virtual)" Invited Speaker. Grand Rounds, University of Iowa, Carver College of Medicine, Department of Neurology (2021)
  • "Panelist and Board Presentation, Executive Leadership in Academic Medicine (Virtual)" Case Study for the Ann Preston School of Medicine, Drexel University (2021)
  • "Pathways of Achieving Gender Equity in Medicine (Virtual)" Invited Speaker. Grand Rounds, Harvard Medical School, Brigham and Women’s Hospital, Department of Neurology (2021)
  • "Careers in Neurology, Conversation Corner: How to Find a Mentor (Virtual)" Presenter. 2021 American Association of Neurology Annual Meeting (2021)
  • "Aligning Academic Medicine within the Healthcare System (Virtual)" Invited Speaker. American Pediatric Society, Society for Pediatric Research, Virtual Symposium (2021)
  • "Pathways to Advancing Gender Equity in Medicine & Health Sciences" Keynote. The Women in Health Sciences Fall Event (2020)
  • "Invited Panel Speaker. The Pivot: Communicating About How Public Universities Rise During Global and National Crises" Association of Public & Land-grant Universities Council on Strategic Communications Panel (2020)
  • "The Importance of Gender Equity" Keynote Speaker. 2020 Women's International Day Summit (2020)
  • "Invited Plenary Speaker. Presidential Symposium: Genetic Heterogeneity & Phenotypic Pleiotropy in the Nextgen Sequencing Era, ATP1A3 Disorders, from Gene Discovery to Expanding Phenotypic Spectrum" Child Neurology Society (2019)
  • "Invited Speaker. Session II: RDP Phenotypes: The Tip of the Iceberg?" Eighth Symposium ATP1A3 in Disease: Towards the Light (2019)
  • "Academic Institutions of the Future" Keynote Speaker. 2019 Internal Medicine Faculty Development Symposium (2019)
  • "Clinical Faculty Development and Sustainability; Recruitment and Retention, Promotional Pathway, Burnout, the Evolving Workforce, HR, Faculty Development, Gen X, Millennials and Reduced FTE: Issues for Family" Invited Speaker. American Academic of Neurology Annual Meeting (2019)
  • "Clinical Usefulness of Botulinum Toxin for Spasticity Skills Workshop" Course Director. American Academy of Neurology Annual Meeting (2019)
  • "Navigating Your Career - Negotiation Skills" Invited Speaker. American Academy of Neurology Annual Meeting (2019)
  • "Want Women to Advance in Medicine: Be a Sponsor" Invited Speaker. Grand Rounds, Weill Cornell Medicine, New York Presbyterian Hospital (2019)
  • "Combining Patient Care, Research and Education to Improve Care; Lessons from Neuroscience" Wake Forest Baptist Health Dean's Forum - Neurosciences (2018)
  • "American Neurological Association, 143rd Annual Meeting, AUPN Chair Career Level course, Tips in Recruitment for a Diverse Workforce" American Neurological Association, 143rd Annual Meeting (2018)
  • "Clinical Symptoms Pharmacologic Treatment: Dystonia and Parkinsonism" 7th Annual Symposium on ATP1A3 in Disease (2018)
  • "Course Director. Spasticity Workshop" American Academy of Neurology Fall Conference (2018)
  • "Invited Speaker. American Academy of Neurology Industry Roundtable. Women in Neurology: Challenges and Need for Change" American Academy of Neurology Fall Conference (2018)
  • "Invited Speaker. Genotype/Phenotype Relationships in Neurological Disease Research, One Gene Many Phenotypes: Pleiotropy" 143rd Annual American Neurological Association Meeting (2018)
  • "Invited Speaker. MOC: Life-long Learning for Neurologists" 143rd Annual American Neurological Association Meeting (2018)
  • "Planning Committee and Speaker. Want Change? Sponsor a Woman to Lead" Breakthrough to Brave Conference, Wake Forces Baptist Medical Center (2018)
  • "Career Development for Clinician Educators" Course Director. American Academy of Neurology, Annual Meeting (2018)
  • "Clinical Usefulness of Botulinum Toxin for Spasticity Skills Workshop" Course Director. American Academy of Neurology, Annual Meeting (2018)
  • "Course Director. Clinical Usefulness of Botulinum Toxin" American Academy of Neurology Annual Meeting (2018)
  • "Interviewing Skills: Negotiation" American Academy of Neurology, Annual Meeting (2018)
  • "Invited Speaker. Interviewing Skills: Negotiation. (Mentoring Session)" American Academy of Neurology Annual Meeting (2018)
  • "Invited Speaker. Mentoring Session: Navigating Your Career: Development for Clinician Educators" American Academy of Neurology Annual Meeting (2018)
  • "Navigating Your Career I" American Academy of Neurology, Annual Meeting (2018)
  • "What I Wish I Knew" Association of University Professors of Neurology, New Chairs Luncheon (2018)
  • "Women in Neurology: Crafting Your Leadership Career: Lessons from Leaders" American Academy of Neurology Meeting, HeadTalks Work Group (2018)
  • "Understanding Academic Finances Session" office of Women in Medicine and Science Career Development for Women Leaders Program, Wake Forest Baptist Medical Center (2018)
  • "Chair. Panel Discussion: NINDS Early Career Research Training Symposium" Chair. Panel Discussion: NINDS Early Career Research Training Symposium. American Academy of Neurology Annual Meeting (2017)
  • "Course Director. Clinical Usefulness of Botulinum Toxin" American Academy of Neurology Annual Meeting (2017)
  • "Invited Speaker. Interviewing Skills: Negotiation. Mentoring Session" American Academy of Neurology Annual Meeting (2017)
  • "Botulinum Toxin in Treatment of Upper Extremity Spasticity" Toxins 2017: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins (2017)
  • "Invited Speaker. ATP1A3 Disease: Lessons Learned from My Patients" Neurology Grand Rounds, Duke University Medical Center (2017)
  • "Course Director. Career Development for Clinician Educators" American Academy of Neurology Annual Meeting (2016)
  • "Course Director. Clinical Usefulness of Botulinum Toxin for Spasticity Skills Workshop" American Academy of Neurology Annual Meeting (2016)
  • "Director. Career Development for Clinician Educators (four-year term)" American Academy of Neurology Annual Meeting (2016)
  • "Speaker. Career Development for Clinician Educators Getting Hired and Promoted in Medical Education" American Academy of Neurology Annual Meeting (2016)
  • "Speaker. How to be Successful in Academic Neuroscience Research Methodology, Education and History" American Academy of Neurology Annual Meeting (2016)
  • "Chair Panel member. NINDS/ANA Career Development Symposium" American Neurological Association Annual Meeting (2016)
  • "Meet the Chairs (lunch workshop/round table discussion)" American Neurological Association Annual Meeting (2016)
  • "DYT12 Story: Patients and Team Science and The Use of Botulinum Toxin for Spasticity" Guest Lecturer. Western Intermountain Neurological Organization, University of Utah (2016)
  • "Invited Speaker. Disease of ATP1A3: Learning from Our Patients" Grand Rounds, University of Pittsburgh (2016)
  • "Where are we with ATP1A3 Related Disease Today" 5th Annual Symposium on ATP1A3 Disease, Neuroscience Hospital, Queen Square (2016)
  • "Course Director. Career Development for Clinician Educators" American Academy of Neurology Annual Meeting (2015)
  • "Course Director. Leadership for Women" American Academy of Neurology Annual Meeting (2015)
  • "Director. Career Development for Clinician Educators (four-year term)" American Academy of Neurology Annual Meeting (2015)
  • "Panel Member. Research Career Development Symposium: How to be Successful in Academic Neuroscience" American Academy of Neurology Annual Meeting (2015)
  • "ATP1A3: A Spectrum or Distinct Phenotypes?" 13th International Conference on Rare Diseases, Rare Diseases Crossing Borders Together (2015)
  • "Alternating Hemiplegia of Childhood and Rapid Onset Dystonia-Parkinsonism" 19th International Congress of Parkinson’s Disease and Movement Disorders. 5311 Teaching Course (2015)
  • "ATP1A3: Insights from our Patients with Dystonia" John Bradbury Penney, Jr, M.D. Memorial Lecture at Massachusetts General Hospital (2015)
  • "Plenary speaker. Spasticity: Rating Scales" Toxins 2015: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins (2015)
  • "Co-chaired consensus meeting of experts in AHC and RDP with Dr. Swoboda" AHC Family Meeting (2014)
  • "Co-Director. Women in Leadership" American Academy of Neurology, Annual Meeting (2014)
  • "Director. Career Development for Clinician Educators (four-year term)" American Academy of Neurology Annual Meeting (2014)
  • "Research Career Development Symposium: How to Be Successful in Academic Neuroscience" American Academy of Neurology 66th Annual Meeting (2014)
  • "AUPN Special Interest Group, Mentoring Junior Faculty" American Neurological Association Annual Meeting (2014)
  • "Chair Panel with Q&A. NINDS/ANA Career Development Symposium" American Neurological Association Annual Meeting (2014)
  • "Chair, Session I: Genetics and Phenotype/Genotype Correlation I AHC/RDP" ATP1A3 International Symposia (2014)
  • "Genotype/Phenotype Correlations, Modelling, and Identification of Potential Targets for Treatment" Third Symposium ATP1A3 in Disease (2014)
  • "Speaker, Session II: ATP1A3 Mutations, An Expanding Phenotype and Plenary Speaker" ATP1A3 International Symposia (2014)
  • "The phenotypic spectrum and pathologic mechanism of ATP13A2 mutations and study of UDP_4694; Kathleen Sweadner (MGH) & Allison Brashear (Wake Forest)" UDP Translational Laboratory Webinar (2014)
  • Plenary Speaker. ATP1A3 International Symposia (2013)
  • "BoNT for Limb Spasticity and Dystonia Botulinum Toxins: Practical Issues and Clinical Uses for Neurologists" American Academy of Neurology 65th Annual Meeting (2013)
  • "Chair Panel with Q&A. NINDS/ANA Career Development Symposium" American Neurological Association (2013)
  • "Clinical Practice Survival Guide" American Academy of Neurology 64th Annual Meeting (2013)
  • "Course Director. Leading in a Complex World" American Academy of Neurology 65th Annual Meeting (2013)
  • "Director. Career Development for Clinician Educators (four-year term)" American Academy of Neurology Annual Meeting (2013)
  • "Dystonia Skills Workshop" American Academy of Neurology, Fall Conference (2013)
  • "Faculty. Career Development for Clinician Educators" American Academy of Neurology 65th Annual Meeting (2013)
  • "Faculty. Research Career Development Symposium" American Academy of Neurology Annual Meeting (2013)
  • "Leadership Lecture for Chairs. Managing a Department of Neurology in a Changing World" American Neurological Association (2013)
  • "Rapid Onset Dystonia Parkinsonism (RDP)" Grand Rounds, Wake Forest University School of Medicine, Department of Neurology (2013)
  • Plenary Speaker. ATP1A3 International Symposia (2012)
  • "Faculty. Research Career Development Symposium" American Academy of Neurology Annual Meeting (2012)
  • "Treating Parkinson’s Today: Our Role in the Latest Advances (Faculty)" Dean’s Forum: Wake Forest School of Medicine (2011)
  • "Dystonia Skills Workshop, Botulinum Toxin: New and Emerging Therapies Uses. The Use of Botulinum Toxin in Adult Spasticity – Upper and Lower Limb" American Academy of Neurology (2011)
  • "Botulinum Toxins: Practical Issues and Clinical Uses for Neurologist" American Academy of Neurology 63rd Annual Meeting (2011)
  • "Clinical Usefulness of Botulinum Toxin and Treatment of Dystonia" American Academy of Neurology 63rd Annual Meeting (2011)
  • "Faculty. Career Develop Symposium: Transitioning from Residency to Research" American Academy of Neurology 63rd Annual Meeting (2011)
  • "Management of Spasticity" American Academy of Neurology 63rd Annual Meeting (2011)
  • "Rapid Dystonia Parkinson" Invited Speaker. Grand Rounds, Medical College of Georgia (2011)
  • "American Academy of Neurology Academic/Research Panel" 62nd Annual Meeting of the American Academy of Neurology (2010)
  • "Speaker. Botulinum Toxin: New and Emerging Uses" American Academy of Neurologists Fall Conference (2010)
  • "The Evidence Basis for the Team Approach; Clinical Overview: Upper Motor Neuron Syndrome/Spasticity" Course Director. Comprehensive Clinical Management Workshop (2010)
  • "The Evidence Basis for the Team Approach; Clinical Overview: Upper Motor Neuron Syndrome/Spasticity; Video Grand Rounds" Course Director. Comprehensive Clinical Management Workshop (2010)
  • "Botulinum Toxins: Practical Issues and Clinical Uses for Neurologists" American Academy of Neurology’s 62nd Annual Meeting (2010)
  • "Clinical Usefulness of Botulinum Toxin and Treatment of Dystonia" American Academy of Neurology’s 62nd Annual Meeting (2010)
  • "Keynote Speaker" 2010 Canadian Botulinum Toxin Conference (2010)
  • "Invited Speaker" Fourth Annual Neuroscience Conference, Graylyn Conference Center (2009)
  • "Invited Speaker. Comprehensive Clinical Management Workshop" Beth Israel Medical Center and Scientiae LLC (2009)
  • "Faculty Speaker. 2AC.004: Botulinum Toxins: Practical Issues and Clinical Uses for Neurologists (CME)" American Academy of Neurology’s 61st Annual Meeting (2009)
  • "Invited Speaker. Dystonia/Spasticity Workshop" American Academy of Neurology Fall Conference (2007)
  • "Cervical Dystonia; Other Indications for Botulinum Toxin," Invited Speaker. The Uses of Botulinum Toxin in Dystonia and Related Disorders Workshop, Duke University School of Medicine (CME) (2007)
  • "Rapid Onset-Dystonia Parkinsonism (RDP): Bedside to Bench" Invited Speaker. Grand Rounds (Intramural), National Institute of Neurological Disorders and Stroke, National Institutes of Health (2007)
  • "Visiting Faculty. Dystonia and Spasticity Training Course, Botulinum Toxin: A Primer" Johns Hopkins University School of Medicine (2007)
  • "Development of a new PRO for clinical studies with NT201 for patients with lower/upper limb spasticity" Invited Speaker. Expert Panel Meeting (2007)
  • "Course Director. Clinical Usefulness of Botulinum toxin and Treatment of Dystonia" American Academy of Neurology Annual Meeting (2007)
  • "The Phenotypic Spectrum of Rapid-Onset Dystonia-Parkinsonism (RDP) Associated with Mutations in the ATP1A3 Gene" Grand Rounds, University of North Carolina at Chapel Hill (2007)
  • "Invited Speaker. Dystonia/Spasticity Workshop" American Academy of Neurology Winter Conference (2007)
  • "The Use of Botulinum Toxin in the Treatment of Spasticity" Grand Rounds, Medical University of South Carolina (2006)
  • "The Role of Botulinum Toxin in the Treatment of Hand Syndrome" Invited Speaker. Veteran’s Administration Caribbean Healthcare System (2006)
  • "Musculoskeletal Uses of Botulinum Toxins" Invited Speaker. The American Orthopaedic Association Annual Meeting (2006)
  • "Rapid Onset Dystonia Parkinsonism" Invited Speaker. The Neurogenetic Commission of the Polish Academy of Sciences (2006)
  • "Botulinum toxins: Practical issues and Clinical uses for Neurologists" American Academy of Neurology Annual meeting (2006)
  • "Course Director. Clinical Usefulness of Botulinum Toxin and Treatment of Dystonia" American Academy of Neurology Annual Meeting (2006)
  • "The Spectrum of Neurologic Uses of Botulinum Toxin Type A from Head to Toe" Speaker. Neurology Update for the Primary Care Provider, Hawthorne Inn (CME) (2006)
  • "Invited Presenter. Commission on Accreditation of Rehabilitation Facilities Conference" Medical Rehabilitation/Aging Services (2006)
  • "Functional Outcomes in Post Stroke Spasticity" Grand Rounds, Wake Forest University School of Medicine (2005)
  • "Invited Speaker. National Stroke Association Meeting" National Stroke Association Meeting (Southeast) (2005)
  • "Invited Speaker. National Stroke Association Meeting" National Stroke Association Meeting (Southeast) (2005)
  • "Botulinum Toxin for Neurological Disease" Grand Rounds, Rosalind Franklin University of Medicine and Science department of Neurology (2005)
  • "Botulinum toxins: Practical issues and Clinical uses for Neurologists" American Academy of Neurology Annual meeting (2005)
  • "Course Director. Clinical Usefulness of Botulinum Toxin and Treatment of Dystonia" American Academy of Neurology Annual Meeting (2005)
  • "The Dystonia Program at Indiana University School of Medicine: Botulinum toxin and Rapid-Onset Dystonia-Parkinsonism" Visiting Professor. University of Miami School of Medicine Department of Neurology (2005)
  • "Course co-director. Botulinum toxin: Scientific Program Skill Workshop" Movement Disorders Society (2005)
  • "RDP Story" Grand Rounds, University of Chicago Department of Neurology (2005)
  • "Invited Speaker. Use of botulinum toxin in treatment of spasticity" Special all day education forum on pain and spasticity. Dept of Physical Medicine and Rehabilitation, IU School of Medicine (2004)
  • "Course Director. Clinical Usefulness of Botulinum Toxin and Treatment of Dystonia" American Academy of Neurology Annual Meeting (2004)
  • "Treatment of Hemifacial Spasms with Botulinum Toxin" Grand Rounds, Indiana University School of Medicine, Department of Neurosurgery (2004)
  • "Benefits of BOTOX® in Improving Spasticity" Grand Rounds, Toronto Rehab MSA (2003)
  • "Invited Speaker. Western Stroke Consortium" Western Stroke Consortium (2003)
  • "A Multicenter, Double-Blind and Open-Label Study of the Safety and Efficacy of Repeated Botulinum Toxin Type A Doses in Post-Stroke, Focal and Upper Limb Dystonia" Grand Rounds, Department of Rehabilitation, IU School of Medicine (2003)
  • "Spasticity Management" Special Grand Rounds guest speaker Department of Physical Medicine and Rehabilitation, Indiana University School of Medicine (2003)
  • "Functional improvement in stroke patients after treatment with botulinum toxin type A" Guest Speaker. Grand Rounds, Department of Clinical Neurosciences, Royal College of Physicians and Surgeons of Canada (2003)
  • "Faculty Member, Update in the Clinical Neurosciences (CME Course)" Indiana University School of Medicine, Department of Neurology (2002)
  • "Grand Rounds" Indiana University School of Medicine, Department of Neurology (2002)
  • "Invited Speaker. Botulinum Toxin Type A: The Evidence Reviewed" 13th European Congress of Physical and Rehabilitation Medicine, Satellite Symposium (2002)
  • "Invited Speaker. “A Multicenter, double-blind, randomized, placebo-controlled, parallel study of the safety and efficacy of BOTOX® purified neurotoxin in the treatment of focal upper limb spasticity post-stroke" BOTOX® zur Behandlung fokaler Spastizität –Symposium (Botox® Spasticity Program) (2002)
  • "Invited Speaker and Course Lecturer. Dystonia: Workshop for the Use of Botulinum Toxins" The Movement Disorder Society (2001)
  • "Director and Course Lecturer. Dystonia: Workshop for the Use of Botulinum Toxins" The Movement Disorder Society (2001)
  • "Botulinum toxin in the Treatment of Dystonia" Invited Lecturer. Grand Rounds, Vanderbilt University, Department of Neurology (2001)
  • "New Botulinum Therapy for the Treatment of Movement Disorders" Invited Lecturer. Grand Rounds, St. Louis University, Department of Neurology (2001)
  • "The Role of EMG in Chemodenervation: Application for Spasticity, Cervical Dystonia, and Disorders of Increased Muscle Tone" Invited Instructor. American Academy of Electrodiagnostic Medicine 2000 Workshops (2000)
  • "Chemodenervation Workshop" Invited Faculty. American Academy of Electrodiagnostic Medicine 1999 Workshops in Electrodiagnostic Medicine (1999)
  • "Invited Lecturer. Grand Rounds, University of Louisville, Department of Neurology" Invited Lecturer. Grand Rounds, University of Louisville, Department of Neurology (1999)
  • "New forms of Botulinum Toxin" Guest lecturer. Special Interest Group, American Academy of Electrodiagnostic Medicine 46th Annual Scientific Meeting (1999)
  • "Invited Speaker. Clinical Trial of Botulinum toxin Type B in Type-A responsive patients" New Developments in the Treatment of Cervical Dystonia (1999)
  • "Chemodenervation Workshop" Invited Faculty. American Academy of Electrodiagnostic Medicine 1998 Workshops in Electrodiagnostic Medicine (1998)
  • "Genetics and Dystonia" Guest lecturer. Dystonia Medical Research Foundation Mid-East Annual Symposium (1995)
  • "Chemodenervation: Clinical Applications and New Uses" Guest lecturer. Special Interest Group, American Association of Electrodiagnostic Medicine 42nd Annual Scientific Meeting (1994)
See all (138 more)

Service Activities:

  • University at Buffalo Foundation (UBF); Board Member (2021–present)
  • http://www.buffalo.edu/news/faculty-experts/covid-19.html#health; UB COVID-19 expert: Infectious disease, hospitals, COVID-19 variants. (2021–present)
  • http://www.buffalo.edu/news/experts/allison-brashear-faculty-expert-medical-education-clinical-trials-dystonia-spasticity.html Areas of expertise: Medical education and research, diversity in medicine, women in medicine, community engagement and health equity, clinical trials, treatment of rare neurological disorders, spasticity and dystonia.; UB Faculty experts can provide commentary and analysis on topics in the news (2021–present)
  • http://www.buffalo.edu/news/faculty-experts/covid-19.html#health-disparities; UB Health disparities, impact on vulnerable communities expert (2021–present)
  • http://www.buffalo.edu/news/faculty-experts/covid-19.html#health-professions; UB Medical education, health professions expert (2021–present)
  • University of California Health, Conflict of Interest Working Group - Next Steps; Member (2021)
  • University of California Davis School of Medicine, Funds Flow Executive Steering Committee; Dean, Co-Chair (2021)
  • American Board of Psychiatry and Neurology Committee on Bylaws; Member (2021)
  • American Board of Psychiatry and Neurology Committee on Continuing Certification; Member (2021)
  • University of California, Davis, Dean Search, School of Veterinary Medicine; Committee Member (2021)
  • American Board of Psychiatry and Neurology Certification Examination Combined Committee-Neurology; Vice-Chair (2021–present)
  • University of California Davis School of Medicine, Clinical Strategic Planning Steering Committee; Dean (2020–2021)
  • University of California Davis School of Medicine Alumni Association, Board of Directors; Dean (2020–2021)
  • University of California Davis School of Medicine, Health Conflicts Oversight Committee (HCOC); Dean, Chair (2020–2021)
  • American Neurology Association, Mentor Junior and Early Career Members Virtual Networking Session; Mentor (2020–present)
  • University of California Davis, Mike and Renee Child Institute for Innovation and Entrepreneurship; Academic Advisor (2020–2021)
  • University of California Davis School of Medicine, Human Anatomical Specimens and Tissue Oversight Committee (HASTOC); Dean, Chair (2020–2021)
  • University of California Davis, International Scholars and Researchers Policies and Procedures Committee, Chancellor appointment (2020–2021)
  • University of California Office of the Vice Provost, Working Group relating to the University’s Conflict of Commitment Policies: APM - 025, Conflict of Commitment and Outside Activities of Faculty Members, and APM - 671, Conflict of Commitment and Outside Activities of Health Sciences Compensation Plan Participants; Member (2020–2021)
  • University of California Office of the President, University of California Health, Conflict of Commitment Working Group; Member (2020–2021)
  • University of California Davis, Next Generation Reforms to Advance Campus Safety Task Force, Chancellor appointment; Committee Member (2020–2021)
  • University of California Davis School of Medicine, Aging Initiative Executive Sponsor and Co-Chair of Executive Committee; Dean (2020–2021)
  • University of California Davis School of Medicine, Restore & Renew Executive Committee; Dean, Co-Chair (2020–2021)
  • American Board of Psychiatry and Neurology Executive Committee; Board Member-at-Large (2020-2021), Secretary (2021-2022) (2020–2022)
  • American Board of Psychiatry and Neurology CEO Search Committee; Co-Chair (2020–present)
  • Wake Forest School of Medicine Chair of Physiology and Pharmacology Search Committee; Member (2019–present)
  • University of California Davis Hospital, Governance Advisory Committee; Dean (2019–2021)
  • University of California Davis, Administrative Coordinating Council of Deans; Committee Member (2019–2021)
  • University of California Davis, Campaign Steering Committee; Committee Member (2019–2021)
  • University of California Davis, Diversity and Inclusion Executive Leadership Team; Committee Member (2019–2021)
  • University of California Davis, Provost Leadership Council; Committee Member (2019–2021)
  • University of California Davis School of Medicine, Clinical Leadership Team (CLT); Dean (2019–2021)
  • University of California Davis Medical Group Executive Committee; Dean (2019–2021)
  • University of California Davis Medical Center Medical Staff Executive Committee; Dean (2019–2021)
  • University of California Davis School of Medicine, Compliance Executive Committee (CEC); Dean (2019–2021)
  • University of California Davis School of Medicine, Council of Chairs (COC); Dean (2019–2021)
  • University of California Davis School of Medicine, Faculty Executive Committee (FEC); Dean (2019–2021)
  • University of California Davis School of Medicine, Full-time Equivalent (FTE) Review & Planning Committee; Dean (2019–2021)
  • University of California Davis School of Medicine, Geriatrics Strategic Advisory Committee; Dean (2019–2021)
  • University of California Davis School of Medicine, Health Data Oversight Committee (HDOC); Dean (2019–2021)
  • University of California Davis School of Medicine, Information Technology Steering Committee; Dean (2019–2021)
  • University of California Davis School of Medicine, SOM Space Advisory Committee; Dean (2019–2021)
  • University of California Davis School of Medicine, Surgical Services Steering Committee (SSSC); Dean (2019–2021)
  • University of California Davis School of Medicine, Transplant Executive Committee; Dean, Co-Chair (2019–2021)
  • University of California Davis School of Medicine, Programmatic Support Committee; Dean, Co-Chair (2019–2021)
  • National Health Service, Biomedical Research Centre, Fellowship Application Review; Reviewer (2019)
  • American Board of Psychiatry and Neurology Strategic Planning Committee; Chair (2019–present)
  • American Board of Psychiatry and Neurology Committee on Maintenance of Certification; Member (2019–present)
  • American Board of Psychiatry and Neurology Clinical Neurology Subcommittee for Certification Examination Combined Committee-Neurology; Vice-Chair (2019–present)
  • Wake Forest Baptist Medical Center Committee on Outside Activity; Co-Chair (2018–2019)
  • Wake Forest Baptist Medical Center Ambulatory Clinic Optimization Committee (Health System CEO appointed); Co-Chair (2018–2019)
  • Wake Forest Baptist Medical Center Information Technology Steering Committee (Health System Co-Chair with CIO); Co-Chair (2018–2019)
  • American Board of Psychiatry and Neurology Clinical Neurology Adult Certification Committee; Member (2018)
  • American Board of Psychiatry and Neurology Faculty Innovation in Education Award Committee; Member (2018 to present), Vice-Chair (2019), Chair (2020 to present) (2018–present)
  • Wake Forest Baptist Medical Center, CEO Cabinet (2017–2019)
  • Wake Forest Baptist Medical Center Research Infrastructure and Compensation Workgroup; Member (2017–2019)
  • Wake Forest Baptist Medical Center Industry Trial Growth Workgroup; Member (2017–2019)
  • Wake Forest Baptist Medical Center Master Facility Planning Committee; Member (2017–2019)
  • American Academy of Neurology Leadership Development Committee (AAN President Appointed); Member, Women in Leadership Workgroup (March 2016 to April 2021), Industry Relations Subcommittee (2019) (2017–2021)
  • Wake Forest Baptist Medical Center Faculty Leadership Council; Chair (2017)
  • Wake Forest Baptist Medical Center Faculty Leadership Council; Chair (2017)
  • American Heart Association; Founding President, Triad Board (2017–2019)
  • American Academy of Neurology Membership Committee (AAN President Appointed); Member (2017–2019)
  • American Academy of Neurology Leadership University Mentoring Programs, Diversity Leadership Program: Dr. Jennifer Armstrong, 2017-2018; Mentor (2017–2018)
  • American Board of Psychiatry and Neurology Liaison to Committee of Neurological Societies (2017–present)
  • American Board of Psychiatry and Neurology Liaison to American Neurological Association (2017–present)
  • American Board of Psychiatry and Neurology Liaison to Association for University Professors of Neurology; Member (2017–present)
  • Wake Forest School of Medicine Chair of Department of Radiology Search Committee (2016–present)
  • Wake Forest School of Medicine Chair of Department of Emergency Medicine Search Committee (2016–present)
  • Wake Forest School of Medicine Chief Human Resources Officer Search Committee; Member (2016–present)
  • American Academy of Neurology Gender Disparity Task Force; Member (2016–2018)
  • Wake Forest Baptist Medical Center Women’s Leadership Program Steering Committee; Member (2016–2019)
  • American Academy of Neurology Leadership University Mentoring Programs, Transitioning Leadership Program: Dr. Jennifer Majersik, 2018-2019; Dr. Veeneta Singh, 2016-2017; Dr. Daniela Bota, 2016-2017; Mentor (2016–2019)
  • American Academy of Neurology Navigating Healthcare Reform Task Force; Member (2016–2018)
  • Wake Forest Baptist Medical Center Institutional Conflict of Interest Committee; Member (2016–2017)
  • American Academy of Neurology Leadership University Mentoring Programs, Emerging Leaders Program: Dr. Katharina M. Bush, 2016-2017; Mentor (2016–2017)
  • ZNS1 SRB-B (52) 1 NST-1 (K Awards); Reviewer. Added as permanent appointment January 2016 to present. Co-Chair (June 2016, October 2016, February 2017), Chair (September 2018-2019) (2016–present)
  • Wake Forest School of Medicine Director of Center for Integrative Medicine Search Committee (2015–present)
  • Wake Forest School of Medicine Search Committee for Director for Center of Healthcare Innovation and Transformation (2015–present)
  • Wake Forest Baptist Medical Center Financial Systems Program, Program Advisory Team; Member (2015–2016)
  • American Academy of Neurology Meeting Management Committee (AAN President Appointed); Member (2015–2019)
  • The Winston-Salem Foundation (parent organization of the Women's Fund of Winston-Salem); Member, Community Philanthropy Builders Committee (2015–2019)
  • American Heart Association (record dollars raised $640,000 and $500,000); Chair, Winston-Salem Heart & Stroke Walk (2015–2017)
  • American Board of Psychiatry and Neurology Committee on Finance; Member (2015–present)
  • American Board of Psychiatry and Neurology Investment Committee; Member (2015–present)
  • American Board of Psychiatry and Neurology Neurology Council (2015 to present), Executive Committee (January 2019 to present); Member (2015–present)
  • American Board of Psychiatry and Neurology Committee on Research and Development; Member (2015-present), Vice-Chair (2019), Chair (2021) (2015–present)
  • Wake Forest Baptist Medical Center JCCG Finance Committee, September 2015 to July 2019 JCCG Strategy and Growth Committee, October 2014 to July 2019 JCCG Operations and IT Council, October 2014 to July 2019; Member, Executive Council of Clinical Chairs (ECCC), Joint Council of Clinical Governance (JCCG) (subcommittees: quality, finance, operations, and strategy) (2014–2019)
  • Wake Forest Baptist Medical Center EDW Steering Committee; Chair (2014–2015)
  • Wake Forest Baptist Medical Center, Executive Director, Behavioral Health Service Line (2014–2015)
  • Wake Forest School of Medicine Chair of Department of Pediatrics Search Committee (2014–2019)
  • Wake Forest School of Medicine VP Population Health and Director of Center for Health Care Innovation and Transformation Search Committee (2014–2015)
  • Wake Forest Baptist Medical Center Neuro-ICU Steering Committee; Member (2014–2016)
  • Wake Forest School of Medicine Chair of Department of Internal Medicine Search Committee (2014–present)
  • Wake Forest Baptist Medical Center Business Analytics Taskforce; Member (2014)
  • Executive Leadership in Academic Medicine (ELAM) Admission Selection Committee, College of Medicine, Drexel University, Pennsylvania; Member (2014–2022)
  • American Board of Psychiatry and Neurology Committee on MOC Examination-Neurology; Member, Chair (2018 to present) (2014–2021)
  • Women's Fund of Winston-Salem; Member (Emeritus), Advisory Board (2014–2019)
  • Wake Forest Baptist Medical Center Faculty Compensation Advisory Committee Funds Flow Subcommittee – Chair Departmental Compensation Plan Template Review Subcommittee 2018; Member, Faculty Compensation Advisory Committee (2014–2019)
  • Department of Defense: CDMRP Dystonia PRMRP; Reviewer (2014–2018)
  • Committee Chair, Wake Forest School of Medicine Chair of Department of Family Medicine Search Committee (2013–2014)
  • Wake Forest School of Medicine, Junior Faculty Mentoring Program; Mentor (2013–2019)
  • Wake Forest School of Medicine McCreary Cyclic Mood Disorders Chair Search Committee (2013–2014)
  • Wake Forest Baptist Medical Center Governing Board Campaign Division Committee; Member (2013–2016)
  • Wake Forest Baptist Medical Center Enterprise Data Warehouse Committee; Member (2013–2014)
  • Wake Forest Baptist Medical Center Alzheimer's Disease Center Planning Committee; Member (2013–2016)
  • Wake Forest Baptist Medical Center Physician Network Strategy Engagement Committee; Member (2013–2016)
  • Wake Forest School of Medicine Finance and Business Affairs Committee, Wake Forest Baptist Medical Center Board of Directors; Finance and Business Affairs Committee, Wake Forest Baptist Medical Center Board of Directors (2013–2015)
  • Wake Forest Baptist Medical Center Clinical Strategic Cabinet; Member (2012–2013)
  • Wake Forest Baptist Medical Center Accelerated Transformation Initiative; Team Leader, Management Reporting (2012–2014)
  • American Neurological Association Membership/Honorary Awards Committee; Member (2012 to 2015), Co-chair (2015 to 2017), Chair (2018) (2012–2018)
  • American Academy of Neurology Medical Economics and Management Committee (AAN President Appointed); Member (2011–2015)
  • Wake Forest School of Medicine Health Systems Operations and Quality Committee, Wake Forest Baptist Medical Center Board of Directors; Member, (2011–2015)
  • Women's Fund of Winston-Salem; Chair, Board of Directors (2011–2013)
  • Wake Forest School of Medicine Audit and Compliance Committee, Wake Forest Baptist Medical Center Board of Directors; Member, (2011–2013)
  • Wake Forest School of Medicine Chair Department of Obstetrics and Gynecology Search Committee (2011–2012)
  • Wake Forest School of Medicine Dean Search Committee (2010–2011)
  • Wake Forest School of Medicine Academic Affairs Committee, Wake Forest Baptist Medical Center Board of Directors; Member, (2010–2013)
  • Dystonia Medical Research Foundation Scientific Advisory Committee; Reviewer (2010–2013)
  • American Academy of Neurology Board of Directors Nominating Committee (AAN President Appointed); Member (2010)
  • Women's Fund of Winston-Salem; Vice Chair, Board of Directors (2010)
  • Advisory Board, 3rd Annual Johns Hopkins Dystonia & Spasticity Practicum (2009)
  • Wake Forest School of Medicine Chair, Patient Safety Subcommittee, and Quality & Service Excellence Committee, Wake Forest Baptist; Medical Center Board of Directors (2009–2010)
  • American Academy of Neurology Program Accreditation and Development Subcommittee; Member (2009–2015)
  • American Academy of Neurology Education Committee (AAN President Appointed); Member (2009–2015)
  • Women's Fund of Winston-Salem; Member, Board of Directors (2009–2014)
  • American Academy of Neurology Leadership Task Force Committee (AAN President Appointed); Member (2009–2012)
  • Women's Fund of Winston-Salem; Chair, Grants Committee (2009–2010)
  • Wake Forest School of Medicine, Career Development for Women Leaders, Program, Women's Health Center of Excellence Research Awards Day Selection Committee, Chair 2009, Member 2007, 2010; Mentor (2009–2010)
  • Member; Governor Mike Easley's appointee to Home Health Ad Hoc Task Force of the NC State Health Coordinators Council (2008)
  • Grants Committee; Women's Fund of Winston-Salem; Member (2008)
  • Wake Forest School of Medicine Bio-molecular Imaging Oversight Committee (2007–2014)
  • WE MOVE Cervical Dystonia Ad Hoc Committee; Member (2007–2013)
  • Wake Forest School of Medicine, Board of Directors, Wake Forest Baptist Medical Center (one of two faculty appointments); Member, (2007–2013)
  • American Neurological Association Budget and Finance Committee; Member (2007–2010)
  • Wake Forest School of Medicine North Carolina Baptist Hospital Finance Committee, Wake Forest Baptist Medical Center Board of Directors; Member, (2007–2010)
  • Wake Forest School of Medicine General Clinical Research Center Human Subjects Protection Committee (2007–2008)
  • Wake Forest School of Medicine. Women’s Health Center of Excellence for Research, Leadership, Education; Mentor (2007)
  • Wake Forest School of Medicine Faculty Academic Appeals Committee; Chair, 2010, Member (2006–2010)
  • Wake Forest Baptist Medical Center (Pre-Integration) Access Ad Hoc Committee, Wake Forest University Physicians; Member (2006–2007)
  • American Neurological Association Nominating Committee; Member (2006–2020)
  • Wake Forest School of Medicine LCME Self-Study Section - MD Degree Portion; Co-Chair (2006–2008)
  • American Neurological Association Public Policy Committee; Member (2006–2007)
  • Wake Forest School of Medicine Recruitment, Retention, Promotions, and Tenure Committee (2005–2008)
  • Wake Forest Baptist Medical Center Faculty Executive Committee; Member (2005–2019)
  • Wake Forest Baptist Medical Center, WFBMC reformatted all service lines in 2014 with revenue/expense responsibility - $135 million, integrated practice unit development; Executive Director of Neuroscience Service Line (2005–2019)
  • WE MOVE Education Committee; Member (2005–2013)
  • Wake Forest Baptist Medical Center (Pre-Integration) Chiefs of Professional Services Executive Committee; Member (2005–2009)
  • Wake Forest Baptist Medical Center (Pre-Integration) Wake Forest University Physicians Council; Member (2005–2008)
  • National Stroke Association, Rehabilitation and Recovery Review Advisory Board; Invited Member (2004–2008)
  • Member, Medical Executive Committee. Rehabilitation Hospital of Indiana, Indianapolis, IN (2004–2005)
  • Fellow of the American Neurological Association (2004)
  • Indiana University School of Medicine Dean's Appointment Chair of Clinical Research Strategic Planning Committee (Charged with making recommendations for doubling research dollars in next nine years.) (2003–2004)
  • Dystonia Spasmodic Torticollis Professional Advisory Board; Member (2003–2015)
  • Indiana University School of Medicine Vice-Chair of Clinical Practice, Department of Neurology Development (2003–2005)
  • Indiana University School of Medicine Department of Neurology Clinical Practice Committee (incentive plan, coding, compensation, service standards); Chair (2003–2005)
  • Indiana University School of Medicine Practice Plan Hospital Committee: University Hospital Operations/Facility Committee (reviews major capital budgets for IU Hospital); Invited Member (2003–2005)
  • Indiana University School of Medicine Dean's Appointment AAMC Graduation Questionnaire Committee (Charged with making recommendations for culture change based on GQ rsuslts.); Chair (2003–2005)
  • Indiana University School of Medicine Practice Plan Business Affairs Committee of IUMG-SC; Invited Member (2002–2005)
  • Member; Governor Frank O’Bannon's appointee to Governor’s Task Force on Alzheimer’s Disease and Other Senile Dementia (2001–2003)
  • American Academy of Neurology Dystonia/Spasticity Advisory Panel; Member (2001 to 2003), Chair (2004 to 2013) (2001–2013)
  • Indiana University-Purdue University Indianapolis Fringe Benefits Standing Committee (2000–2004)
  • Indiana University School of Medicine Dean's Appointment Task Force on Professional and Educational Environment (2000–2002)
  • Indiana University School of Medicine Elected Secretary University Clinical Neurology (2000–2005)
  • Indiana University-Purdue University Indianapolis Fringe Benefits Standing Committee (1998–1999)
  • Indiana University School of Medicine Women's Mentoring Program (1998–2003)
  • Indiana University School of Medicine Dean's Appointment GCRC Advisory Committee (1997–1998)
  • Dystonia Study Group; Founding Member (1996 to 2014), Nominating Committee (2008) (1996–2014)
  • Indiana University School of Medicine Women's Mentoring Program (1996)
  • Indiana University Healthcare Associates Ambulatory Care Committee; Member (1995–1996)
  • Indiana University School of Medicine Dean's Appointment Teacher-Learner Advocacy Committee; Chair (2000-2005), Student Advisor (2004), Member (1994-2000) (1994–2005)
  • Indiana University Hospital Credentials Committee; Member (1994–1998)
  • Indiana University School of Medicine Medical Director, Outpatient Services for Department of Neurology (1993–2003)
  • Member; Governor Evan Bayh's appointee to Occupational Licensing Committee of the Health Professions Bureau (served two consecutive terms) (1992–2002)
  • Indiana University School of Medicine Associate Director of University Hospital Neurology Outpatient Clinics (1991–1993)
  • Clinical Neuroscience and Neurodegeneration Study Section, Brain Disorders and Clinical Neuroscience Integrated Review Group, Center for Scientific Review, CNN, Agenda Sequence Number 417039; Reviewer
  • ZNS1 SRB-H (17), Udall Centers P50 Review, Agenda Sequence Number 410494; Reviewer
  • Academic Program Review of the Department of Neurology, Massachusetts General Hospital; External Consultant (Chair of Review Committee)
  • Academic Program Review of the Collaborative Center for X-Linked Dystonia Parkinsonism, Massachusetts General Hospital; Member
  • American Academy of Neurology Women Leading in Neurology Selection Committee; Member
  • Academic Program Review of the Department of Neurology, Massachusetts General Hospital; External Consultant (Chair of Review Committee)
  • Academic Program Review of the Department of Neurology, Brown Albert Medical School, Rhode Island; Member
  • NSD-K Ad Hoc Reviewer; Reviewer
  • Wake Forest Baptist Medical Center Clinical Informatics Affinity Group; Member
  • CNN Review; Reviewer
  • ZNS1 SRG-G (03) Clinical Trials in Neurological Disorders; Reviewer
  • Special Emphasis Panel/Scientific Review Group 2015/01 N/1ST-1 (NINDS) (K AWARDS); Reviewer
  • ZNS1 SRB-B (52) 1 NST-1 (K Awards); Reviewer
  • ZNS1 SRB-G (81) (Clinical Trial Section); Reviewer
  • Special Emphasis Panel/Scientific Review Group 2015/01 N/1ST-1 (NINDS) (K AWARDS); Reviewer
  • Academic Program Review of the Department of Neurology, San Francisco General Hospital, University of California, San Francisco; External Consultant
  • Special Emphasis Panel/Scientific Review Group 2015/01 N/1ST-1 (NINDS) (K AWARDS); Reviewer
  • ZNS1 SRB EO2; Reviewer
  • Wake Forest Baptist Medical Center Same Day Access Taskforce turned into Operations Committee of ECCG; Member
  • Wake Forest Baptist Medical Center Faculty Manpower Planning Taskforce, Subcommittee of Compensation Advisory; reorganized into People Committee of JCCG; Chair
  • NINDS ZNS1 SRB-G75, Clinical R25 Review Panel; Reviewer
  • NINDS ZNS1 SRB-G 78-Special Emphasis Panel/Scientific Review Group; Reviewer
  • Wake Forest Baptist Medical Center Health System Management Board; Member
  • Wake Forest Baptist Medical Center Health System Medical Executive Operations Committee; Member
  • Wake Forest School of Medicine Psychiatry Chair Confirmation Committee; Chair
  • Wake Forest School of Medicine Chair of Department of Dermatology Search Committee
  • Wake Forest Baptist Medical Center Capital Campaign Steering Committee and Council (two faculty only); Member
  • Meeting Chair, The Fourth Annual Johns Hopkins Dystonia & Spasticity Practicum
  • Neurotoxin Institute Advisory Council; Member
  • Wake Forest Baptist Medical Center Faculty Compensation Committee; Member
  • Dissertation Panel, Calderon Dissertation, Beth Israel Hospital, New York; External Consultant
  • Wake Forest University Physicians Board of Directors; Invited Guest
  • Wake Forest University Physicians Finance Subcommittee; Member
  • Wake Forest Baptist Medical Center Strategic Planning Steering Committee; Member
  • Academic Program Review of the Department of Neurology, University of Arizona; External Consultant
  • Wake Forest Baptist Medical Center (Pre-Integration) Regional Practice Steering Committee; Member
  • Wake Forest Baptist Medical Center (Pre-Integration) Contracting Committee, Wake Forest University Physicans; Member
  • NIH NINDS NSD-A Study Section; Reviewer
  • Indiana University-Purdue University Indianapolis Issues of Power in the Educational Setting Panel; Abuse or Respect Workshop; Teacher-Learner Advocacy Committee
  • American Board of Psychiatry and Neurology; Invited Examiner for Oral Boards (11/93, 04/94, 05/95, 06, 95, 04/96, 03/98, 11/98 National)
  • Wake Forest University Physicians Practice Plan (dissolved); Member
  • American Board of Psychiatry and Neurology Committee on Irregular Behavior; Member (2015, 2018, 2019, 2021)
  • American Board of Psychiatry and Neurology Committee to Review Appeals-Neurology; Member (2017, 2018, 2019, 2021)

School News:

In the Media:


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

955 Main Street, Room 6190
Buffalo, New York 14203-1121
Phone: (716) 829-3955
Fax: (716) 829-2179
brashear@buffalo.edu